{"meta":{"query_hash":"f341d2f9e313","filters":{"venue":"Clinical Pharmacology in Drug Development"},"cohort_total":57,"direct_labels_cover":0,"predictions_cover":57,"exported":57,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f341d2f9e313","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Pharmacology+in+Drug+Development"},"results":[{"id":"W1904376711","doi":"10.1002/cpdd.27","title":"Impact of Tesamorelin, a Growth Hormone‐Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Adrenal Hormones and Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Ritonavir; Simvastatin; Cmax; Medicine; Pharmacokinetics; Pharmacology; CYP3A; Crossover study; Regimen; Dosing; Internal medicine; Immunology; Placebo; Human immunodeficiency virus (HIV)","score_opus":0.04274883741436251,"score_gpt":0.39492696586806947,"score_spread":0.35217812845370694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1904376711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490625,0.00079269207,0.00001610546,0.0029651446,0.0001671713,0.0009903449,0.0000120012255,0.000011955161,0.00013831083],"genre_scores_gemma":[0.994954,0.0020859241,0.000657563,0.0021312588,0.00005470419,0.000058976228,0.0000151709,0.00002102147,0.00002136297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973265,0.00027188697,0.0014151304,0.00034182912,0.00024268507,0.00040196016],"domain_scores_gemma":[0.99758565,0.0015966342,0.00029738736,0.0001274476,0.00016873724,0.0002241519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004728362,0.00024020419,0.0007131992,0.00023695682,0.000037231588,0.0000042289184,0.00016130664,0.00012972018,0.00021044903],"category_scores_gemma":[0.00038602753,0.0001598089,0.00013050878,0.00037665336,0.00041800746,0.00005071658,0.00010484367,0.0006760358,0.000015163765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054028565,0.00379128,0.92516834,0.00020936274,0.0004653109,0.000058957437,0.0032011424,0.00021258241,0.007916717,0.00003176372,0.024212405,0.029329257],"study_design_scores_gemma":[0.0063020126,0.0010395794,0.9892805,0.00008312155,0.000042501626,0.0000052078412,0.00036712328,0.0016870183,0.0008045143,0.000092046525,0.00013946393,0.00015688491],"about_ca_topic_score_codex":0.00069611036,"about_ca_topic_score_gemma":0.00003511902,"teacher_disagreement_score":0.064112164,"about_ca_system_score_codex":0.00013122834,"about_ca_system_score_gemma":0.00043680865,"threshold_uncertainty_score":0.6516818},"labels":[],"label_agreement":null},{"id":"W2069868586","doi":"10.1002/cpdd.196","title":"Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients","year":2015,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Covariate; Population; Demographics; Metabolite; Active metabolite; Internal medicine; Pharmacology; Oncology; Demography; Statistics; Environmental health","score_opus":0.15163782514833876,"score_gpt":0.4866974679411927,"score_spread":0.33505964279285394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069868586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965584,0.00097004545,0.000011095052,0.00056980154,0.00051303045,0.00085652317,0.00000554363,0.000011644161,0.00050386635],"genre_scores_gemma":[0.9971134,0.0009898478,0.00085094373,0.0005895042,0.00009934858,0.00014575501,0.000030495117,0.0000137221,0.00016695331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764794,0.00035936406,0.001049172,0.00034427224,0.0002693081,0.00032996814],"domain_scores_gemma":[0.99887913,0.00035896958,0.0001524538,0.00006904557,0.00026752602,0.00027287175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013684237,0.00015062206,0.0007845711,0.0002598189,0.000023189803,0.0000020454272,0.00009774718,0.00015140422,0.000099804056],"category_scores_gemma":[0.00045108693,0.00013305483,0.000035777448,0.00027100882,0.00008802299,0.00008060593,0.00013067016,0.00049005327,0.000009710073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013142495,0.0013228569,0.98499393,0.00009338519,0.00014984151,0.000025515335,0.0015720717,0.0005965036,0.00025873398,0.000007723995,0.00034646044,0.00931872],"study_design_scores_gemma":[0.012848788,0.00014014829,0.9151419,0.0000932795,0.00014740352,0.0000020111156,0.00011317396,0.06976503,0.0011776239,0.00010844495,0.00032654827,0.00013566022],"about_ca_topic_score_codex":0.00020972994,"about_ca_topic_score_gemma":0.000067268105,"teacher_disagreement_score":0.06985205,"about_ca_system_score_codex":0.00028337643,"about_ca_system_score_gemma":0.00061650865,"threshold_uncertainty_score":0.5425818},"labels":[],"label_agreement":null},{"id":"W2097275353","doi":"10.1002/cpdd.87","title":"Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase‐4 inhibitor","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"","keywords":"Medicine; Dipeptidyl peptidase-4; Dipeptidyl peptidase-4 inhibitor; Pharmacokinetics; Pharmacology; Dipeptidyl peptidase; Population; Diabetes mellitus; Type 2 diabetes; Endocrinology; Biochemistry; Enzyme; Environmental health","score_opus":0.023717635637227237,"score_gpt":0.3603088754721077,"score_spread":0.3365912398348805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097275353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509066,0.00009989862,0.000020497419,0.0008747836,0.0006263619,0.001407507,0.000002882158,0.00006089499,0.0018164819],"genre_scores_gemma":[0.99329317,0.00008189209,0.002226597,0.0017081526,0.0001629921,0.0004214131,0.00016716217,0.000020667407,0.0019179605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972307,0.00021608725,0.0013506996,0.0005114532,0.00027919727,0.00041183687],"domain_scores_gemma":[0.9987306,0.00037361635,0.00031017247,0.00017657876,0.00019242596,0.00021663384],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068832026,0.00025029003,0.00096035126,0.0007576739,0.00004428859,0.000009134726,0.00013642672,0.00011603817,0.0016800998],"category_scores_gemma":[0.00008475938,0.00021885797,0.00025842933,0.0011991761,0.00011969883,0.00010832213,0.00014155527,0.00030476655,0.00018910611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026933185,0.0030831846,0.92228484,0.000104023806,0.006207502,0.000039663482,0.0008870039,0.0002166396,0.0030080536,0.00001550479,0.03232425,0.03156],"study_design_scores_gemma":[0.004662582,0.00015382026,0.98042166,0.00004661791,0.0027353002,6.1504795e-7,0.00007569616,0.0018037349,0.0067105833,0.000039828537,0.0031422824,0.00020729826],"about_ca_topic_score_codex":0.00009627559,"about_ca_topic_score_gemma":0.000047526384,"teacher_disagreement_score":0.0581368,"about_ca_system_score_codex":0.00026045318,"about_ca_system_score_gemma":0.00011324322,"threshold_uncertainty_score":0.9992325},"labels":[],"label_agreement":null},{"id":"W2123762312","doi":"10.1002/cpdd.35","title":"Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Pfizer; Amgen","keywords":"Medicine; Panitumumab; Irinotecan; Pharmacokinetics; Colorectal cancer; Oncology; Pharmacology; Internal medicine; Cancer; Cetuximab","score_opus":0.029883549016545604,"score_gpt":0.3673054002709479,"score_spread":0.33742185125440227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123762312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973356,0.0001855034,0.000004763575,0.00057616434,0.00016705609,0.0014915845,0.0000060663633,0.000012876541,0.00022037583],"genre_scores_gemma":[0.9968954,0.00022891194,0.0017813639,0.0004204132,0.000026095235,0.00053496996,0.000016729533,0.000016138129,0.000080024896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844944,0.0000960966,0.00065615936,0.00033296162,0.00020739202,0.00025796503],"domain_scores_gemma":[0.9992945,0.00015712113,0.00018618284,0.000060183287,0.0001777419,0.00012424163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019845406,0.00020429766,0.0006004287,0.00011358568,0.00003668185,0.0000059743916,0.00005576232,0.000044555865,0.0001729591],"category_scores_gemma":[0.000020720994,0.00013642697,0.000021463216,0.0002019867,0.00031935892,0.00006390152,0.000053030402,0.00025780586,0.000003477848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031460505,0.001703792,0.9780089,0.000080897174,0.00039743652,0.00001887346,0.0008641567,0.00001404835,0.00009892386,0.00000165661,0.0002947227,0.015370535],"study_design_scores_gemma":[0.01705534,0.0015762628,0.9778934,0.00012337486,0.00020268139,0.0000030057604,0.00014749038,0.00007467548,0.0024318383,0.0000064684905,0.00032780212,0.00015763032],"about_ca_topic_score_codex":0.00018495967,"about_ca_topic_score_gemma":0.0010178076,"teacher_disagreement_score":0.015212905,"about_ca_system_score_codex":0.00017726503,"about_ca_system_score_gemma":0.0004244642,"threshold_uncertainty_score":0.55633307},"labels":[],"label_agreement":null},{"id":"W2141030907","doi":"10.1002/cpdd.48","title":"Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Pharmacokinetics; Oncology; Internal medicine; Volume of distribution; Response Evaluation Criteria in Solid Tumors; Cancer; Clinical trial; Pharmacology; Phases of clinical research","score_opus":0.05145983826760502,"score_gpt":0.42960602247205204,"score_spread":0.378146184204447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141030907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583936,0.00015356058,0.000024215946,0.00046456544,0.00086168497,0.0019699598,0.000009290446,0.000019045418,0.0006582982],"genre_scores_gemma":[0.99483734,0.00038624927,0.002612885,0.0007369702,0.00008770507,0.0008181164,0.000023217635,0.00003594697,0.0004615939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968768,0.00033660358,0.001298044,0.00046055336,0.00040576293,0.00062226155],"domain_scores_gemma":[0.998091,0.0009006824,0.00028899458,0.0001861138,0.0002637803,0.00026941826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040924546,0.00027783687,0.0012184161,0.00025620265,0.00003968475,0.000005033979,0.000216731,0.00011329649,0.0044485945],"category_scores_gemma":[0.00014227178,0.00021215307,0.00006833385,0.0003525264,0.00044719325,0.00007955136,0.00013662272,0.00063733564,0.00006251795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006846498,0.00207527,0.97370595,0.00019171741,0.000885298,0.000032021977,0.0007310932,0.00012270304,0.00060422847,0.0000028930338,0.0021338733,0.012668431],"study_design_scores_gemma":[0.049696513,0.0006533604,0.9444703,0.0002228868,0.0004357848,7.278649e-7,0.00015010986,0.00083628704,0.002618029,0.000018305449,0.0006529585,0.0002447673],"about_ca_topic_score_codex":0.00046603192,"about_ca_topic_score_gemma":0.00038002327,"teacher_disagreement_score":0.042850014,"about_ca_system_score_codex":0.0006400103,"about_ca_system_score_gemma":0.0014550182,"threshold_uncertainty_score":0.99646145},"labels":[],"label_agreement":null},{"id":"W2158520906","doi":"10.1002/cpdd.189","title":"Effect of lapatinib on oral digoxin absorption in patients","year":2015,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"GlaxoSmithKline","keywords":"Lapatinib; Digoxin; Medicine; Pharmacokinetics; Pharmacology; Therapeutic index; Oral administration; Drug interaction; Metastatic breast cancer; Absorption (acoustics); Concomitant; Breast cancer; Drug; Internal medicine; Cancer; Trastuzumab; Heart failure","score_opus":0.03924627127115151,"score_gpt":0.3940237622506233,"score_spread":0.3547774909794718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158520906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620163,0.000024642264,0.0000068528284,0.00030050916,0.0017268904,0.000758482,0.0000018838595,0.00002211106,0.000957005],"genre_scores_gemma":[0.9982917,0.000020510537,0.00047339205,0.0006516244,0.000065798464,0.000067484194,0.00005035223,0.00001523324,0.00036390548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978434,0.0003212878,0.0009796969,0.0003046684,0.00028472388,0.0002662112],"domain_scores_gemma":[0.9991815,0.00030399594,0.00014542772,0.00011251872,0.00007228422,0.00018426623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024643901,0.00016523458,0.00061787665,0.00018445119,0.000012985238,0.0000015693162,0.000109845045,0.00015582972,0.00007958749],"category_scores_gemma":[0.0001548412,0.00012675446,0.00007309994,0.00020907876,0.00009414919,0.000032559896,0.000031137817,0.00041595395,0.000080122816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075353263,0.002376806,0.96470606,0.0001326757,0.00005635072,0.00008731573,0.000651608,0.00004158835,0.00027135466,0.000013630048,0.003348849,0.020778442],"study_design_scores_gemma":[0.027238304,0.0017357799,0.9270819,0.00021993919,0.000054788507,5.605851e-7,0.000032812794,0.000047301957,0.038708676,0.000041621326,0.004662498,0.00017584684],"about_ca_topic_score_codex":0.000009621851,"about_ca_topic_score_gemma":0.000047728932,"teacher_disagreement_score":0.038437318,"about_ca_system_score_codex":0.0001765967,"about_ca_system_score_gemma":0.00022673496,"threshold_uncertainty_score":0.5168897},"labels":[],"label_agreement":null},{"id":"W2347141072","doi":"10.1002/cpdd.269","title":"Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Pegfilgrastim; Medicine; Biosimilar; Confidence interval; Pharmacodynamics; Pharmacokinetics; Crossover study; Bioequivalence; Clinical endpoint; Internal medicine; Pharmacology; Surrogate endpoint; Filgrastim; Randomized controlled trial; Granulocyte colony-stimulating factor; Placebo; Chemotherapy","score_opus":0.08186570106038771,"score_gpt":0.4648163808401086,"score_spread":0.3829506797797209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2347141072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876732,0.000045433382,0.00027837837,0.007417152,0.0011899434,0.0031683657,0.000022332915,0.000040053583,0.0001650953],"genre_scores_gemma":[0.99432296,0.00019980114,0.0009220624,0.003633092,0.00013494989,0.0006734578,0.000020414816,0.00002821504,0.000065074935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958225,0.0005843019,0.0021352482,0.00066223263,0.00025378822,0.0005419224],"domain_scores_gemma":[0.99816614,0.00089331286,0.00024554748,0.00019837359,0.0002039972,0.0002926004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025289017,0.00027035354,0.00090190076,0.0006322056,0.00004727897,0.0000053598537,0.00023999128,0.00015671688,0.00027001038],"category_scores_gemma":[0.00018436751,0.00022035769,0.00011220577,0.00059941097,0.00023348455,0.0001430176,0.00008698604,0.0005281629,0.00001639312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010128092,0.011577164,0.9390546,0.00025237468,0.000254566,0.0001083641,0.0011900555,0.00026121968,0.019688042,0.00002260939,0.0043435064,0.013119419],"study_design_scores_gemma":[0.04646017,0.0021128762,0.9357362,0.00018673137,0.00022693978,0.0000085012025,0.00026815623,0.0032620283,0.006385911,0.000071290946,0.0049205227,0.0003606888],"about_ca_topic_score_codex":0.00010936568,"about_ca_topic_score_gemma":0.0014328731,"teacher_disagreement_score":0.03633208,"about_ca_system_score_codex":0.00057254,"about_ca_system_score_gemma":0.00092749234,"threshold_uncertainty_score":0.8985926},"labels":[],"label_agreement":null},{"id":"W2531615040","doi":"10.1002/cpdd.319","title":"Comparison of the Pharmacokinetics of Ketorolac Tromethamine After Continuous Subcutaneous Infusion and Repeat Intramuscular Bolus Injections in Healthy Adult Subjects","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmacological Receptor Mechanisms and Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"","keywords":"Medicine; Ketorolac Tromethamine; Pharmacokinetics; Anesthesia; Bolus (digestion); Cmax; Crossover study; Intramuscular injection; Ketorolac; Bioavailability; Regimen; Analgesic; Pharmacology; Surgery; Placebo","score_opus":0.017526939900527116,"score_gpt":0.35658175209653215,"score_spread":0.33905481219600503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531615040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965303,0.00075572747,0.00007735488,0.0006131685,0.0013133466,0.0006524906,0.000010235192,0.00000798729,0.00003939869],"genre_scores_gemma":[0.9966062,0.0014969981,0.00052286894,0.0010660258,0.00010969473,0.000108480825,0.000005798316,0.000016703478,0.00006727012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971108,0.0006798906,0.0011872227,0.00047445513,0.00017666676,0.00037099206],"domain_scores_gemma":[0.998791,0.00041545703,0.00033164775,0.00018588257,0.00013225753,0.00014378784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009881825,0.00021944493,0.000576726,0.00010323794,0.00004171403,0.000003088445,0.00026482705,0.00026301653,0.00008373638],"category_scores_gemma":[0.0004323434,0.00014261805,0.000110090186,0.00022408337,0.0003338603,0.000006150604,0.00038324343,0.00032699158,0.0000023693376],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035506056,0.0010876174,0.19727832,0.000083750114,0.00009135806,0.000022790733,0.00027301858,0.000029630766,0.77421767,0.000005735475,0.0011885848,0.02217094],"study_design_scores_gemma":[0.006504141,0.0012339697,0.23884502,0.00011008642,0.000057496636,0.000016005337,0.00006324014,0.00008942177,0.7466451,0.000044398494,0.0061213537,0.00026977927],"about_ca_topic_score_codex":0.000019870608,"about_ca_topic_score_gemma":0.00012382993,"teacher_disagreement_score":0.041566696,"about_ca_system_score_codex":0.00006479096,"about_ca_system_score_gemma":0.00018501421,"threshold_uncertainty_score":0.58157957},"labels":[],"label_agreement":null},{"id":"W2606334551","doi":"10.1002/cpdd.358","title":"Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"Merck","keywords":"Raltegravir; Pharmacokinetics; Bioavailability; Pharmacology; Medicine; Biopharmaceutics; Dosing; Biopharmaceutics Classification System; In vivo; Human immunodeficiency virus (HIV); Chemistry; Virology; Antiretroviral therapy; In vitro; Biological activity; Biology; Viral load; Biochemistry; Pharmacognosy; Biotechnology","score_opus":0.08495309511939617,"score_gpt":0.41743036901476527,"score_spread":0.3324772738953691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606334551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934002,0.00021244693,0.000024420357,0.0027838196,0.00067404966,0.0007805535,0.000009397805,0.000022009886,0.0020931126],"genre_scores_gemma":[0.9805075,0.00046773892,0.015905349,0.00026948447,0.00010052406,0.00003786967,0.000030811345,0.000021877098,0.0026588384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974546,0.00010949152,0.0014580223,0.00039585252,0.00025219168,0.00032988773],"domain_scores_gemma":[0.99802506,0.00065942266,0.0005999003,0.00030627678,0.0001779999,0.00023135287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008348278,0.00024644358,0.00080526574,0.00020300336,0.00014740303,0.000009388248,0.00024515323,0.00014719187,0.00013793848],"category_scores_gemma":[0.00036558445,0.00021240056,0.00011599375,0.000105667576,0.00059046404,0.00010113404,0.00025857438,0.0003261893,0.000018289722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001021389,0.0033553478,0.9116704,0.00022243618,0.00066647213,0.00012499538,0.0023154086,0.000011181669,0.01380762,0.000070685775,0.00622914,0.060504958],"study_design_scores_gemma":[0.019761747,0.00016482455,0.84492475,0.0002302719,0.00033272261,0.000013132438,0.000116813455,0.0006442402,0.1053385,0.00012996764,0.028055895,0.0002871191],"about_ca_topic_score_codex":0.000015476278,"about_ca_topic_score_gemma":0.00004154088,"teacher_disagreement_score":0.091530874,"about_ca_system_score_codex":0.000103357765,"about_ca_system_score_gemma":0.00040810238,"threshold_uncertainty_score":0.86614436},"labels":[],"label_agreement":null},{"id":"W2761677898","doi":"10.1002/cpdd.394","title":"Categorization of Abuse Potential–Related Adverse Events","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Categorization; Adverse effect; Medical emergency; Pharmacology; Artificial intelligence","score_opus":0.13228444398396244,"score_gpt":0.5026786822963262,"score_spread":0.37039423831236373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761677898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814181,0.000116482086,0.00006354698,0.0011525359,0.011927631,0.00076255575,0.000026129032,0.000089576606,0.0044434527],"genre_scores_gemma":[0.9932367,0.0015796907,0.00032516834,0.0015064807,0.0003492225,0.000123422,0.00006877996,0.00003677189,0.0027737152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957811,0.00075301726,0.0018782786,0.0006487136,0.00025331954,0.00068552524],"domain_scores_gemma":[0.99737614,0.00047468234,0.0011456393,0.0004295754,0.00019193855,0.00038204418],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024952893,0.0003623107,0.0006997739,0.0002710603,0.0006531266,0.000007955815,0.0010324011,0.0005210704,0.0018951608],"category_scores_gemma":[0.00021252864,0.00037295884,0.00024527876,0.00020602022,0.00065368874,0.0004415896,0.00027832002,0.001578136,0.0006169853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022291683,0.008074247,0.83622944,0.00026282354,0.0023374823,0.0009511495,0.0056622033,0.014521582,0.067629166,0.000492421,0.03482503,0.02678528],"study_design_scores_gemma":[0.021515764,0.00009407593,0.60244745,0.000102709135,0.0006344206,0.00004095445,0.00038394265,0.0055856938,0.11245398,0.0008772533,0.25475946,0.001104274],"about_ca_topic_score_codex":0.00003549534,"about_ca_topic_score_gemma":0.000033145418,"teacher_disagreement_score":0.23378198,"about_ca_system_score_codex":0.00018480913,"about_ca_system_score_gemma":0.0004946746,"threshold_uncertainty_score":0.9998722},"labels":[],"label_agreement":null},{"id":"W2766447985","doi":"10.1002/cpdd.395","title":"Pharmacokinetics of the BCL‐2 Inhibitor Venetoclax in Healthy Chinese Subjects","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genentech; AbbVie","keywords":"Venetoclax; Medicine; Pharmacokinetics; Pharmacology; Internal medicine; Oncology; Leukemia","score_opus":0.056235550579271334,"score_gpt":0.45602244500090494,"score_spread":0.3997868944216336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766447985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889098,0.00035222943,0.0000013093111,0.004923899,0.0032578155,0.0012621705,0.0000026775765,0.000016966105,0.0012731449],"genre_scores_gemma":[0.9951089,0.0005686301,0.0003762248,0.0025962607,0.0005432598,0.000118853175,0.000004677248,0.00002905383,0.00065413397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996489,0.00040137523,0.0014776575,0.0005112602,0.0004863599,0.0006343667],"domain_scores_gemma":[0.9977057,0.00081589783,0.00041891445,0.0006601953,0.00012700865,0.00027230012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025152296,0.0002365794,0.00073838216,0.00017157465,0.00015139833,0.000012285427,0.00085355586,0.00021571573,0.00019204058],"category_scores_gemma":[0.0012151839,0.00016636068,0.00014079265,0.00028042987,0.00079296326,0.000065555585,0.00083680183,0.0011360663,0.000059764025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006809531,0.0024259393,0.93722427,0.00079436065,0.00027329804,0.0009427112,0.0024398607,0.00030336867,0.0048791417,0.000018087594,0.027139114,0.016750298],"study_design_scores_gemma":[0.05829802,0.00019467146,0.9026196,0.00028935296,0.000045023513,0.000042647054,0.000036931426,0.0030599653,0.017282415,0.00008107896,0.017806793,0.00024352885],"about_ca_topic_score_codex":0.00026384825,"about_ca_topic_score_gemma":0.00045205673,"teacher_disagreement_score":0.05148849,"about_ca_system_score_codex":0.0061643193,"about_ca_system_score_gemma":0.015736219,"threshold_uncertainty_score":0.99765086},"labels":[],"label_agreement":null},{"id":"W2793257861","doi":"10.1002/cpdd.439","title":"Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Tolerability; Pharmacokinetics; Nonsteroidal; Atopic dermatitis; Incidence (geometry); Cohort; Adverse effect; Safety profile; Open label; Pharmacology; Dermatology; Internal medicine","score_opus":0.044324968753877196,"score_gpt":0.42396579361689907,"score_spread":0.37964082486302186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793257861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949939,0.0006590399,0.000018189434,0.0009004054,0.0011366499,0.0013559018,0.000016692604,0.000030697312,0.0008885194],"genre_scores_gemma":[0.99816495,0.00026723946,0.00043615702,0.00049895066,0.00023217832,0.000041252577,0.000025116655,0.000015224777,0.00031894268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961643,0.00058614055,0.00220761,0.00051450904,0.00022077006,0.00030663048],"domain_scores_gemma":[0.9976533,0.0012477081,0.00039834355,0.00025429318,0.0001979816,0.0002483693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012604729,0.00022082085,0.0009720639,0.00017429225,0.000071915674,0.0000026361743,0.00022427434,0.000165959,0.00012385001],"category_scores_gemma":[0.0005793644,0.0001931716,0.000093900024,0.00020483304,0.0011926885,0.000034247478,0.00028215433,0.0003773131,0.00002111796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13127191,0.04707219,0.6948502,0.0010596917,0.0017462063,0.0019945079,0.012378364,0.000008557161,0.005722956,0.000019031364,0.06714465,0.03673174],"study_design_scores_gemma":[0.07894621,0.0033828658,0.8885295,0.00036717652,0.000709124,0.00020706929,0.0008421693,0.00022199574,0.020110702,0.00001753016,0.006393707,0.00027197474],"about_ca_topic_score_codex":0.000010034885,"about_ca_topic_score_gemma":0.0000060879943,"teacher_disagreement_score":0.19367929,"about_ca_system_score_codex":0.000054086628,"about_ca_system_score_gemma":0.00042342342,"threshold_uncertainty_score":0.78773093},"labels":[],"label_agreement":null},{"id":"W2793645751","doi":"10.1002/cpdd.433","title":"Pharmacokinetic Drug Interaction Study of Bazedoxifene and Ibuprofen","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"Pfizer","keywords":"Pharmacokinetics; Ibuprofen; Medicine; Bioequivalence; Crossover study; Pharmacology; Confidence interval; Internal medicine; Urology; Placebo; Pathology","score_opus":0.02197730178811429,"score_gpt":0.38759583798265373,"score_spread":0.36561853619453943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793645751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649805,0.00033029873,0.0000060929196,0.00014744494,0.0017476721,0.0007934931,7.564314e-7,0.000011443005,0.0004647234],"genre_scores_gemma":[0.9980207,0.00028923972,0.00025715798,0.00043513524,0.00037171328,0.00008913416,0.000013049087,0.000016617207,0.0005072155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998116,0.00040211406,0.0007058476,0.0004392094,0.0001026817,0.00023411977],"domain_scores_gemma":[0.99938685,0.00009835805,0.00017203661,0.0001458975,0.000084006395,0.0001128642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008494408,0.0001673943,0.0002763566,0.00008439057,0.000063359585,0.0000049528976,0.00018254388,0.00013075754,0.00005664347],"category_scores_gemma":[0.000052965857,0.00015002773,0.000041907802,0.000116630574,0.00023577944,0.000005272437,0.00027978077,0.00030496772,0.000024811692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045099195,0.017577425,0.23168854,0.00016369182,0.002243622,0.00014331772,0.008866834,0.00008328746,0.5536443,0.000008084528,0.080264226,0.06021749],"study_design_scores_gemma":[0.078977995,0.0042280853,0.097422235,0.000061216386,0.00021211621,0.000024981711,0.0012714306,0.00024842168,0.7823686,0.000021173455,0.034520168,0.0006435786],"about_ca_topic_score_codex":0.000013542356,"about_ca_topic_score_gemma":0.000036314334,"teacher_disagreement_score":0.2287243,"about_ca_system_score_codex":0.000019124396,"about_ca_system_score_gemma":0.00010188855,"threshold_uncertainty_score":0.6117953},"labels":[],"label_agreement":null},{"id":"W2800574556","doi":"10.1002/cpdd.458","title":"A Study of the Potential Interaction Between Bazedoxifene and Atorvastatin in Healthy Postmenopausal Women","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"Pfizer","keywords":"Atorvastatin; Cmax; Medicine; Pharmacokinetics; Pharmacology; Dosing; Urology; Internal medicine","score_opus":0.04281427300583475,"score_gpt":0.40654031695031073,"score_spread":0.363726043944476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800574556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960034,0.00007074066,0.0000063422262,0.0013137448,0.0011133092,0.0014174477,0.0000013181349,0.000011025278,0.00006267653],"genre_scores_gemma":[0.99741095,0.000058556823,0.0002735297,0.001591291,0.0004814247,0.00013213888,0.000002507037,0.00001278997,0.000036789483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972154,0.00075080513,0.0010846389,0.00035561158,0.00026889524,0.0003246858],"domain_scores_gemma":[0.99919116,0.00017738281,0.0001877563,0.00019352845,0.00008146232,0.00016869546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030527336,0.00013084845,0.00058623706,0.0001281924,0.00006817079,0.0000037375191,0.00011272269,0.0000919402,0.000064641055],"category_scores_gemma":[0.000101238176,0.00009509754,0.000044714645,0.00026483464,0.00017546152,0.00003935882,0.00020431174,0.0005233591,0.0000091383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030817224,0.003425097,0.9099318,0.00013505915,0.0005110009,0.00010510824,0.0140921185,0.000005129938,0.00041838118,0.0000023750688,0.0006439187,0.06764833],"study_design_scores_gemma":[0.009666651,0.0017472034,0.9837924,0.000049137936,0.000054116023,0.000015418782,0.0021840616,0.00001584792,0.000550419,0.000019497977,0.0018177918,0.000087422566],"about_ca_topic_score_codex":0.00017025699,"about_ca_topic_score_gemma":0.0002449214,"teacher_disagreement_score":0.073860675,"about_ca_system_score_codex":0.00027290513,"about_ca_system_score_gemma":0.00053218706,"threshold_uncertainty_score":0.3877965},"labels":[],"label_agreement":null},{"id":"W2803358008","doi":"10.1002/cpdd.473","title":"Tramadol Hydrochloride at Steady State Lacks Clinically Relevant QTc Interval Increases in Healthy Adults","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Veterinary Pharmacology and Anesthesia","field":"Veterinary","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Tata Consultancy Services; Janssen Research and Development; Janssen Scientific Affairs; Valeant Pharmaceuticals International","keywords":"Medicine; Placebo; Tramadol; QT interval; Anesthesia; Moxifloxacin; Adverse effect; Tramadol Hydrochloride; Crossover study; Nausea; Internal medicine; Analgesic; Antibiotics","score_opus":0.0815724810782293,"score_gpt":0.4292402465489839,"score_spread":0.3476677654707546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803358008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234486,0.00020093177,0.0000104370265,0.0020919652,0.0033050883,0.0010904344,0.000028136676,0.00018973823,0.0007384041],"genre_scores_gemma":[0.9806663,0.0004762332,0.0013215685,0.015333878,0.0010008572,0.0003372055,0.000061905834,0.00007495424,0.00072714756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990557,0.0023622825,0.003924021,0.0015466383,0.00033016986,0.0012799009],"domain_scores_gemma":[0.9948787,0.0033359262,0.00064821314,0.00042374522,0.00012846228,0.00058495713],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0040882127,0.0006116095,0.0013024989,0.00032802156,0.00024036874,0.000019493547,0.00098483,0.00049165863,0.0033422778],"category_scores_gemma":[0.00034689062,0.0005981709,0.00023065094,0.0003967297,0.0010145355,0.00024030775,0.0009128385,0.0017282165,0.0034306364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33690867,0.013221842,0.5218759,0.00029038696,0.0007381693,0.02188929,0.010907108,0.000032403812,0.0038864447,0.000011999977,0.054609805,0.035627965],"study_design_scores_gemma":[0.030751878,0.011146206,0.8336703,0.00055628474,0.00011694643,0.00053019467,0.0004985859,0.0015104254,0.0017629234,0.00035373386,0.117431164,0.0016713712],"about_ca_topic_score_codex":0.00028917874,"about_ca_topic_score_gemma":0.001027326,"teacher_disagreement_score":0.31179437,"about_ca_system_score_codex":0.0006143758,"about_ca_system_score_gemma":0.0006338417,"threshold_uncertainty_score":0.99964696},"labels":[],"label_agreement":null},{"id":"W2806608475","doi":"10.1002/cpdd.581","title":"Pharmacokinetics of Perampanel in Healthy Korean, White, and Japanese Adult Subjects","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Perampanel; Pharmacokinetics; White (mutation); Pharmacology; Adverse effect; Genetics","score_opus":0.050979633929201226,"score_gpt":0.4227265915702705,"score_spread":0.37174695764106924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806608475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226683,0.00034672106,0.0000015606863,0.004262729,0.00057177246,0.0008782487,0.000004133541,0.00002258431,0.0016454424],"genre_scores_gemma":[0.99195033,0.0015349363,0.0018242889,0.0038080805,0.00026352718,0.00010439571,0.000021210839,0.0000205084,0.0004727131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716806,0.00033365205,0.0011599748,0.000499195,0.0002725896,0.00056653516],"domain_scores_gemma":[0.9984049,0.00058378803,0.00013744427,0.00016631791,0.0002582089,0.00044934946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012271783,0.00021372407,0.000664487,0.00029568994,0.000046434154,0.0000046302466,0.00013798168,0.00014761242,0.00046106597],"category_scores_gemma":[0.00029046275,0.00018020262,0.00005694382,0.00037284486,0.0006235611,0.000043560594,0.00016138246,0.00058571575,0.000054572243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045884773,0.002817086,0.9694949,0.00021580576,0.00015916293,0.00038301843,0.004256655,0.0000016035287,0.00093943736,0.000007136809,0.0074932757,0.009643438],"study_design_scores_gemma":[0.020828623,0.0016364487,0.9626824,0.00016431212,0.0000622275,0.000042666074,0.00047844945,0.000330018,0.010548411,0.00003456291,0.0029748494,0.00021701226],"about_ca_topic_score_codex":0.00009708499,"about_ca_topic_score_gemma":0.00044248262,"teacher_disagreement_score":0.016240144,"about_ca_system_score_codex":0.00016753384,"about_ca_system_score_gemma":0.0006084347,"threshold_uncertainty_score":0.7348449},"labels":[],"label_agreement":null},{"id":"W2807342171","doi":"10.1002/cpdd.471","title":"Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Pfizer","keywords":"Janus kinase inhibitor; Medicine; Tofacitinib; Dosing; Pharmacokinetics; Psoriasis; Volume of distribution; Renal function; Plaque psoriasis; Internal medicine; Body surface area; Creatinine; Body mass index; Clearance; Gastroenterology; Pharmacology; Urology; Immunology; Rheumatoid arthritis","score_opus":0.01935625667845373,"score_gpt":0.303296412492652,"score_spread":0.28394015581419824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807342171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954042,0.0000842966,0.000021454418,0.0003082769,0.0028826657,0.0008766422,0.00011489174,0.000035150668,0.0002724615],"genre_scores_gemma":[0.99705946,0.00014842558,0.0005710374,0.0010527687,0.00016991312,0.00023595295,0.00024958182,0.000029457595,0.00048337207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968182,0.0005152404,0.0013242615,0.00063175533,0.000080713115,0.0006298683],"domain_scores_gemma":[0.99872655,0.00041116547,0.00029427084,0.00020459338,0.00027225818,0.000091168076],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054698973,0.00035036035,0.00078919565,0.00028500828,0.00008922514,0.0000056797844,0.0003568054,0.00028790248,0.0012111891],"category_scores_gemma":[0.00008316787,0.00030097048,0.00007168879,0.0003781854,0.00031996449,0.000073250194,0.00017271563,0.00039452044,0.00051527156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011202115,0.0035670435,0.7893414,0.00009901635,0.0009792335,0.00006709058,0.0032495137,0.000049267393,0.0053584855,0.000023148807,0.0073794373,0.17868423],"study_design_scores_gemma":[0.024306921,0.0006216537,0.8790224,0.00016285578,0.00014713372,0.000005593285,0.00004895711,0.00001932559,0.078166835,0.000013153161,0.016955554,0.00052957254],"about_ca_topic_score_codex":0.000029745748,"about_ca_topic_score_gemma":0.00020678251,"teacher_disagreement_score":0.17815466,"about_ca_system_score_codex":0.00023405762,"about_ca_system_score_gemma":0.0004325058,"threshold_uncertainty_score":0.99994427},"labels":[],"label_agreement":null},{"id":"W2888696165","doi":"10.1002/cpdd.607","title":"Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"Pfizer","keywords":"Medicine; Pharmacokinetics; Renal function; Selective estrogen receptor modulator; Placebo; Internal medicine; Osteoporosis; Impaired renal function; Postmenopausal women; Urology; Estrogen receptor; Cancer","score_opus":0.008928351467708354,"score_gpt":0.3344801991064224,"score_spread":0.32555184763871403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888696165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980267,0.00023470205,0.000010291723,0.000056651188,0.00093261525,0.00040230394,0.0000018578742,0.000002283136,0.00033258428],"genre_scores_gemma":[0.998757,0.00035543865,0.0002976585,0.00035202323,0.000091869704,0.000037049474,0.0000065404683,0.00001007504,0.00009233155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983715,0.00038612925,0.0006600695,0.00025690187,0.00012485555,0.00020054467],"domain_scores_gemma":[0.9992933,0.00021528587,0.00024133307,0.00013329684,0.00005648545,0.00006026432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008128311,0.00013051466,0.0003047459,0.000075220516,0.00002176236,0.0000012082764,0.00016119279,0.00016931671,0.000013058345],"category_scores_gemma":[0.00008861945,0.00009701818,0.0000421465,0.00014598267,0.0004107303,0.0000022372287,0.00019112106,0.0002526485,7.6770795e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006741909,0.00081209966,0.03455224,0.000108691514,0.00019739941,0.000011821365,0.00022223471,0.00003404923,0.9594908,0.000018729783,0.00062990835,0.0032478813],"study_design_scores_gemma":[0.0029670324,0.0014520108,0.36518958,0.000063486776,0.000031701184,0.0000012906493,0.0000153274,0.000031452142,0.62927413,0.000023840486,0.0008717107,0.00007843007],"about_ca_topic_score_codex":0.0000035758844,"about_ca_topic_score_gemma":0.000004977615,"teacher_disagreement_score":0.33063734,"about_ca_system_score_codex":0.000034548524,"about_ca_system_score_gemma":0.00018640594,"threshold_uncertainty_score":0.39562866},"labels":[],"label_agreement":null},{"id":"W2889013879","doi":"10.1002/cpdd.608","title":"Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Levothyroxine; Bioequivalence; Medicine; Bioavailability; Pharmacokinetics; Crossover study; Randomization; Capsule; Oral administration; Dosage form; Pharmacology; Internal medicine; Randomized controlled trial; Placebo; Hormone","score_opus":0.2020510462544798,"score_gpt":0.4820193330155821,"score_spread":0.2799682867611023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889013879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905738,0.0016027055,0.000052713087,0.005376148,0.0007382439,0.0005364764,0.0000057379584,0.000023383354,0.0010907823],"genre_scores_gemma":[0.99193364,0.0013248469,0.0036420138,0.002614183,0.00024560324,0.00002768583,0.0000053425442,0.0000072209773,0.00019948988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979347,0.00031259342,0.0008741593,0.00042192894,0.00013605069,0.00032054397],"domain_scores_gemma":[0.99853814,0.0007359753,0.00019944177,0.000088670924,0.00018852172,0.00024928356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016873511,0.00018625353,0.0006491588,0.00006990647,0.00011186671,0.000006082998,0.00007894027,0.000104466264,0.0003321394],"category_scores_gemma":[0.00022138585,0.00015370715,0.00003984026,0.00017627388,0.0016004682,0.0000768391,0.00027430867,0.00044871483,0.000025444255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01070606,0.007376102,0.5903697,0.0009715133,0.002170697,0.00013117505,0.011659759,0.0000029729129,0.12962233,0.00013325323,0.117589965,0.1292665],"study_design_scores_gemma":[0.013653551,0.0008235376,0.54493695,0.00007427006,0.00048396128,0.000035058732,0.00039331516,0.0030150318,0.11840974,0.00012614709,0.31766748,0.0003809417],"about_ca_topic_score_codex":0.000040504387,"about_ca_topic_score_gemma":0.0000694697,"teacher_disagreement_score":0.20007752,"about_ca_system_score_codex":0.000059432772,"about_ca_system_score_gemma":0.00015480869,"threshold_uncertainty_score":0.6267996},"labels":[],"label_agreement":null},{"id":"W2906348647","doi":"10.1002/cpdd.643","title":"Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With <i>BRAF</i> <sup>V600</sup> Mutation–Positive Metastatic Malignancy","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Vemurafenib; Medicine; Pharmacokinetics; Pharmacology; Area under the curve; Dosing; Rifampicin; Confidence interval; Internal medicine; Gastroenterology; Urology; Metastatic melanoma; Cancer; Pathology; Tuberculosis","score_opus":0.01646367025858358,"score_gpt":0.3114050173212828,"score_spread":0.2949413470626992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906348647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983308,0.00006398036,0.000026012602,0.00008332675,0.00022347028,0.0008792715,0.000027400472,0.0000032301857,0.00036253888],"genre_scores_gemma":[0.9987236,0.000020755564,0.0005456829,0.00046046686,0.000059941656,0.00006793179,0.000062334235,0.000017468898,0.000041786785],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99745584,0.00079082977,0.00097018736,0.00034197065,0.00019682506,0.00024434752],"domain_scores_gemma":[0.9984826,0.0006641058,0.00040798564,0.00019230659,0.00019172094,0.00006127318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011066049,0.0002066295,0.00047304214,0.00010006025,0.000028101722,0.0000020971972,0.000263735,0.000096123724,0.000046087025],"category_scores_gemma":[0.00018127738,0.0001404581,0.00007618639,0.00021843266,0.00045596279,0.0000047568005,0.00011851796,0.00017555618,0.0000057662774],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026339425,0.012972215,0.4845274,0.00080348004,0.0018597698,0.00010728098,0.007681996,0.0017673398,0.42482823,0.000099961166,0.0056356587,0.03337723],"study_design_scores_gemma":[0.008269846,0.004814955,0.0717115,0.00013212016,0.00009129764,0.0000013368858,0.00004542625,0.000054845175,0.91413283,0.000012396082,0.00057452027,0.00015894082],"about_ca_topic_score_codex":0.000008773456,"about_ca_topic_score_gemma":0.000014800773,"teacher_disagreement_score":0.48930457,"about_ca_system_score_codex":0.000025359479,"about_ca_system_score_gemma":0.00016793009,"threshold_uncertainty_score":0.5727715},"labels":[],"label_agreement":null},{"id":"W2937154946","doi":"10.1002/cpdd.685","title":"Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Pharmacology; Metformin; Pharmacokinetic interaction; Drug interaction; Internal medicine","score_opus":0.05189335607255027,"score_gpt":0.4140086072678435,"score_spread":0.3621152511952932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937154946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362457,0.00019985902,0.000007638319,0.0022008717,0.0008941489,0.0020781874,0.0000017920021,0.000009835223,0.000983079],"genre_scores_gemma":[0.9965234,0.00007607023,0.0020579484,0.00040568897,0.00003180045,0.00012551581,0.000024635083,0.000016187803,0.0007387958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966494,0.0004601579,0.0014391771,0.00034670392,0.0008269285,0.00027762336],"domain_scores_gemma":[0.9987847,0.00033414084,0.00034450987,0.00019432079,0.0002500863,0.00009223277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047177053,0.0001955391,0.0006377818,0.00021302274,0.000026147982,0.000002371933,0.00016473232,0.00010259737,0.00022959638],"category_scores_gemma":[0.00012974528,0.00013364837,0.00010789035,0.00053578714,0.00012192167,0.00006321867,0.00007780494,0.00035570585,0.000021361351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019195561,0.0021144536,0.97594035,0.00016106271,0.0005636507,0.000030849234,0.0020914467,0.0005386182,0.0020670062,0.000014740667,0.000898258,0.013660026],"study_design_scores_gemma":[0.04587925,0.0006240318,0.8637072,0.0005832394,0.0010881444,0.000016174841,0.00077362085,0.0042751147,0.0772495,0.00005166176,0.0054067615,0.00034533624],"about_ca_topic_score_codex":0.000018412764,"about_ca_topic_score_gemma":0.00019586225,"teacher_disagreement_score":0.11223316,"about_ca_system_score_codex":0.00041426555,"about_ca_system_score_gemma":0.0022898302,"threshold_uncertainty_score":0.5450022},"labels":[],"label_agreement":null},{"id":"W2945178990","doi":"10.1002/cpdd.699","title":"Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Methadone; Medicine; Pharmacokinetics; Dosing; Confidence interval; Pharmacology; Drug interaction; Methadone maintenance; Internal medicine","score_opus":0.08319404251493585,"score_gpt":0.4393486597931239,"score_spread":0.35615461727818803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945178990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905162,0.00025226397,0.000005754759,0.0046998025,0.0013456219,0.0015163373,0.0000016439747,0.00001824165,0.0016441214],"genre_scores_gemma":[0.995533,0.0001240485,0.000989522,0.0005188368,0.00012621906,0.00009883747,0.000021680962,0.000015620337,0.0025722503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716824,0.0006419787,0.0009980581,0.0003843158,0.0005766529,0.00023074256],"domain_scores_gemma":[0.9986989,0.00051974284,0.0002551711,0.00017258494,0.00023810554,0.000115505005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004072781,0.000187819,0.00052415003,0.00016246049,0.000040577117,0.0000044679923,0.0001284657,0.00010065401,0.0008959521],"category_scores_gemma":[0.00014462996,0.00013085055,0.0000849133,0.00028859108,0.00013446166,0.000065885084,0.00018270576,0.0004300428,0.00011624076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021716073,0.00063680304,0.87279624,0.00007939297,0.0006831055,0.000006890685,0.0009968053,0.000029474608,0.0023316909,0.000004633795,0.004140302,0.11807752],"study_design_scores_gemma":[0.011627135,0.000057751015,0.9298526,0.00015347051,0.0010077315,0.000010196969,0.00011494047,0.0009091439,0.03136013,0.00007599189,0.0246593,0.00017159978],"about_ca_topic_score_codex":0.0000068138393,"about_ca_topic_score_gemma":0.000012408784,"teacher_disagreement_score":0.117905915,"about_ca_system_score_codex":0.00027310874,"about_ca_system_score_gemma":0.0005417687,"threshold_uncertainty_score":0.9810047},"labels":[],"label_agreement":null},{"id":"W2953947897","doi":"10.1002/cpdd.720","title":"A First‐in‐Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Medicinal Plants and Neuroprotection","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Dosing; Placebo; Randomized controlled trial; Erythema; Single Center; Anesthesia; Internal medicine; Surgery; Pathology","score_opus":0.06716203326062947,"score_gpt":0.42181957715298724,"score_spread":0.35465754389235776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953947897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468726,0.00010535057,0.0000042916827,0.00064630556,0.00095734873,0.0034515343,7.1123316e-7,0.000014989011,0.0001322366],"genre_scores_gemma":[0.9986874,0.00011993364,0.00013966738,0.00075835607,0.000065661094,0.00009371641,0.000005255144,0.000013967553,0.00011605072],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99693793,0.00057693705,0.0015389061,0.00044761217,0.00019638777,0.0003022301],"domain_scores_gemma":[0.99802846,0.0014607026,0.00021228241,0.00011525124,0.00003191776,0.00015136653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034515099,0.00016599691,0.0011411412,0.00039998587,0.000034783614,0.0000029863493,0.00008054119,0.000105338746,0.00016824155],"category_scores_gemma":[0.0005093893,0.00013718131,0.000047951093,0.00022553945,0.0001296671,0.000045946814,0.000075544005,0.0006483245,0.000011450773],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26293328,0.022575784,0.6821166,0.0005754012,0.00020124928,0.0007057492,0.012155773,0.00013050422,0.012815156,0.0000034400275,0.0005957556,0.0051912726],"study_design_scores_gemma":[0.7741159,0.002767749,0.21546558,0.00041353636,0.00007505357,0.00002103318,0.0012091789,0.003462347,0.0013535618,0.000011026607,0.000903774,0.00020125438],"about_ca_topic_score_codex":0.0003253651,"about_ca_topic_score_gemma":0.00073402916,"teacher_disagreement_score":0.5111826,"about_ca_system_score_codex":0.00015048042,"about_ca_system_score_gemma":0.000120326826,"threshold_uncertainty_score":0.55940914},"labels":[],"label_agreement":null},{"id":"W2981182356","doi":"10.1002/cpdd.747","title":"A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV‐0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Biohaven Pharmaceuticals","keywords":"Bioequivalence; Riluzole; Medicine; Pharmacokinetics; Geometric mean; Confidence interval; Adverse effect; Area under the curve; Sublingual administration; Pharmacology; Internal medicine; Amyotrophic lateral sclerosis; Mathematics","score_opus":0.08764181574720296,"score_gpt":0.4492870065205536,"score_spread":0.3616451907733506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981182356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543476,0.00022662237,0.000010613095,0.001180077,0.0007404062,0.0022295106,0.000002042703,0.000030095413,0.00014585674],"genre_scores_gemma":[0.9978324,0.00017156407,0.000709033,0.0008229865,0.00011155761,0.00009116979,0.000016476131,0.000025087778,0.0002196989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960225,0.0005269498,0.0016692318,0.00064275804,0.00047930452,0.0006592514],"domain_scores_gemma":[0.9985497,0.0006049217,0.00021762858,0.00019808173,0.00014542577,0.000284241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029826052,0.00024347824,0.0009459289,0.00043170218,0.00005019764,0.000011180699,0.00025056768,0.00013870643,0.00041192348],"category_scores_gemma":[0.00017391576,0.00022212774,0.00005951267,0.0005868991,0.00019355737,0.00015426938,0.000392525,0.0009094925,0.00006361003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033116273,0.002111814,0.98257357,0.00022079288,0.00010904899,0.000060031205,0.002037875,0.0005503897,0.0053334753,0.0000041753733,0.0006379544,0.003049236],"study_design_scores_gemma":[0.019474136,0.0008179379,0.9613848,0.00013665683,0.000046164994,0.0000059817985,0.00030004414,0.0155042345,0.0010850347,0.000011767983,0.0010220879,0.00021119487],"about_ca_topic_score_codex":0.00048352825,"about_ca_topic_score_gemma":0.00024449622,"teacher_disagreement_score":0.021188822,"about_ca_system_score_codex":0.00034595444,"about_ca_system_score_gemma":0.0004984706,"threshold_uncertainty_score":0.9058106},"labels":[],"label_agreement":null},{"id":"W2992701293","doi":"10.1002/cpdd.753","title":"Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Montreal Clinical Research Institute; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Dosing; Primary immunodeficiency; Pharmacokinetics; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.013220766930134178,"score_gpt":0.2940168658577188,"score_spread":0.2807960989275846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992701293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990496,0.0035505996,0.000010716891,0.00012084679,0.0032252644,0.0008035023,0.0000100714915,0.000037206824,0.0017458174],"genre_scores_gemma":[0.9985121,0.00011933106,0.000097252196,0.00041689904,0.0000033668825,0.00005279039,0.00026520196,0.000023568713,0.0005095259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995986,0.0005861606,0.001818307,0.0007286012,0.00013969761,0.00074124243],"domain_scores_gemma":[0.9982152,0.00079837145,0.00049524254,0.0003452176,0.00012805448,0.000017893528],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014272323,0.00035695825,0.0011734787,0.00096867944,0.00009161482,0.000007654124,0.0006453821,0.00027372583,0.0011988187],"category_scores_gemma":[0.000055668843,0.00031469922,0.00020241628,0.0018310471,0.0004827668,0.00014756582,0.000255989,0.00088618346,0.00025832068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077844984,0.0058740806,0.933239,0.00008856109,0.0027439524,0.000011112476,0.0026007728,0.0028130447,0.016825065,0.000025503254,0.0002583795,0.027736027],"study_design_scores_gemma":[0.021377826,0.0003145292,0.96841097,0.000060891416,0.00044782436,4.2633405e-7,0.0002660475,0.00006284389,0.0037485636,0.0000034344312,0.0048916927,0.0004149557],"about_ca_topic_score_codex":0.00008832079,"about_ca_topic_score_gemma":0.000017112945,"teacher_disagreement_score":0.035171963,"about_ca_system_score_codex":0.00021781813,"about_ca_system_score_gemma":0.00040502878,"threshold_uncertainty_score":0.9999305},"labels":[],"label_agreement":null},{"id":"W3008901859","doi":"10.1002/cpdd.773","title":"Absolute Bioavailability of Vemurafenib in Patients With <i>BRAF</i><sup>V600</sup> Mutation–Positive Malignancies","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Vemurafenib; Medicine; Bioavailability; Mutation; Internal medicine; Cancer research; Oncology; Pharmacology; Cancer; Genetics; Metastatic melanoma; Gene","score_opus":0.018109760222120016,"score_gpt":0.28101741849757805,"score_spread":0.26290765827545803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008901859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980971,0.00009401143,0.00003940207,0.0005349955,0.00019729619,0.0007175207,0.000030169913,0.000010531474,0.00027895105],"genre_scores_gemma":[0.9959898,0.00003209421,0.0013614268,0.0021574646,0.00009973479,0.0000919201,0.00018556174,0.000016720565,0.00006525374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779963,0.00027594424,0.0009003503,0.0005605985,0.00015423496,0.00030924912],"domain_scores_gemma":[0.9992395,0.00011867688,0.0001990395,0.00014688588,0.0001432259,0.00015264457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049871526,0.00020314787,0.00038965145,0.000053135936,0.00003496135,0.00000475635,0.0002480272,0.00017257436,0.00006266226],"category_scores_gemma":[0.00014056459,0.00018160677,0.000064468324,0.00019618525,0.00026655826,0.000008324729,0.00019610705,0.00023503482,0.000025916863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026772157,0.0018194986,0.96822196,0.00012681438,0.00024407262,0.00008104715,0.0033489373,0.00074229727,0.011637321,0.000016153304,0.0061494787,0.0049351812],"study_design_scores_gemma":[0.0069458997,0.00073129055,0.89012986,0.000037386813,0.00002769224,0.000001331065,0.00013737108,0.0000842524,0.089853436,0.000013442212,0.011701673,0.0003363613],"about_ca_topic_score_codex":0.0000101929545,"about_ca_topic_score_gemma":0.000034247612,"teacher_disagreement_score":0.07821611,"about_ca_system_score_codex":0.000038199756,"about_ca_system_score_gemma":0.00035895713,"threshold_uncertainty_score":0.7405709},"labels":[],"label_agreement":null},{"id":"W3011153961","doi":"10.1002/cpdd.789","title":"The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Bioequivalence; Dosing; Tolerability; Pharmacology; Crossover study; Pharmacokinetics; Internal medicine; Placebo; Adverse effect","score_opus":0.03342460266546551,"score_gpt":0.3503987466890036,"score_spread":0.31697414402353813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011153961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741971,0.00786507,0.000020573156,0.016496876,0.00062183,0.00064327393,0.000054737244,0.00001906211,0.000081484905],"genre_scores_gemma":[0.97995645,0.013026896,0.0012463678,0.0051066014,0.00017912779,0.00025344218,0.0000653969,0.000033398734,0.00013232119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964782,0.00047156858,0.0014105092,0.000828423,0.00021540576,0.0005959192],"domain_scores_gemma":[0.99848753,0.00044394555,0.00032834386,0.00035855273,0.00008689873,0.00029472518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010091219,0.00036148934,0.0006361936,0.0000803817,0.00014917555,0.000017561642,0.0007296139,0.00027594404,0.000042302545],"category_scores_gemma":[0.0008066013,0.00029227266,0.00012931804,0.00025324296,0.0009866236,0.000011927222,0.0007702891,0.00039288308,0.000018821564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002522888,0.0016447776,0.73556703,0.0002832057,0.0008525988,0.00012396218,0.0026307974,0.00009815617,0.16817792,0.00006954217,0.07472503,0.013304057],"study_design_scores_gemma":[0.014988267,0.0013029821,0.46609995,0.0001085838,0.00018982765,0.000012742137,0.0018322184,0.00027885055,0.41594502,0.00010984711,0.09806419,0.0010675322],"about_ca_topic_score_codex":0.0001178828,"about_ca_topic_score_gemma":0.0011773619,"teacher_disagreement_score":0.26946712,"about_ca_system_score_codex":0.00009103434,"about_ca_system_score_gemma":0.0005288241,"threshold_uncertainty_score":0.9999529},"labels":[],"label_agreement":null},{"id":"W3017244061","doi":"10.1002/cpdd.788","title":"Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With <i>BRAF</i><sup>V600</sup> Mutation–Positive Malignancies","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Pharmacokinetics; Vemurafenib; Pharmacology; Mutation; Oncology; Internal medicine; Cancer research; Genetics; Cancer; Gene","score_opus":0.018069228122625944,"score_gpt":0.2851740033891128,"score_spread":0.26710477526648685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017244061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847895,0.00008480599,0.000014858955,0.00028248507,0.00013127585,0.00076170085,0.000031735857,0.0000044803455,0.00020970443],"genre_scores_gemma":[0.99883145,0.000038370592,0.00018479743,0.00071158155,0.000058142294,0.00005031235,0.000092522925,0.000017214757,0.000015629867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978158,0.00051345665,0.0009122474,0.0003434926,0.0001909699,0.00022404571],"domain_scores_gemma":[0.9988157,0.00047208095,0.00035329242,0.0001311786,0.00014488846,0.000082864804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006724622,0.00020783668,0.0004619129,0.000057166348,0.000022296945,0.00000248577,0.00026395233,0.00012338854,0.00003564781],"category_scores_gemma":[0.00018572948,0.0001459862,0.000076898694,0.00022376048,0.0002731512,0.000004918107,0.00011910568,0.00020598268,0.0000038836115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014186704,0.0037019416,0.34696016,0.00048817776,0.00060529786,0.0000766475,0.0039460286,0.0042649517,0.61774886,0.00004424074,0.002848211,0.00512881],"study_design_scores_gemma":[0.006470987,0.0030750243,0.08383639,0.00007340326,0.000051453317,7.804169e-7,0.00006454289,0.00007540613,0.9057941,0.000003845179,0.0004057312,0.00014832396],"about_ca_topic_score_codex":0.0000051961456,"about_ca_topic_score_gemma":0.0000060010047,"teacher_disagreement_score":0.28804526,"about_ca_system_score_codex":0.000019821679,"about_ca_system_score_gemma":0.00016804006,"threshold_uncertainty_score":0.59531444},"labels":[],"label_agreement":null},{"id":"W3038254578","doi":"10.1002/cpdd.822","title":"Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady‐State Pharmacokinetics of Vemurafenib in Patients With <i>BRAF</i><sup>V600</sup> Mutation–Positive Malignancies","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Vemurafenib; Itraconazole; Medicine; Pharmacokinetics; Dosing; Pharmacology; Crossover study; Confidence interval; Area under the curve; Internal medicine; Adverse effect; Urology; Gastroenterology; Cancer; Dermatology; Pathology; Metastatic melanoma","score_opus":0.012223719638403855,"score_gpt":0.2778418450221536,"score_spread":0.26561812538374974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038254578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99757737,0.00009887745,0.00002305323,0.0006951075,0.00024919593,0.0010830229,0.000047589194,0.000007806079,0.00021800217],"genre_scores_gemma":[0.9967611,0.000064908876,0.00016876028,0.0026248016,0.00010056366,0.00011170984,0.00010507968,0.000024261237,0.000038855767],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972196,0.00071359414,0.0010103362,0.00047272997,0.00026104096,0.0003226777],"domain_scores_gemma":[0.9987492,0.00048420083,0.0003379342,0.00015286908,0.00014635164,0.00012946525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008611402,0.0002786057,0.00049259653,0.000070895265,0.000040376108,0.000005167812,0.00030980044,0.00013222921,0.000025902536],"category_scores_gemma":[0.00015497151,0.0001956392,0.00009695411,0.00021699148,0.0002751602,0.0000069783423,0.00018426696,0.0003592735,0.0000107971655],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040037226,0.007356582,0.5949381,0.0011085559,0.0019868396,0.00046837638,0.016782988,0.022539135,0.25079492,0.00007469835,0.02202133,0.04189127],"study_design_scores_gemma":[0.010641102,0.0031187774,0.093493134,0.00009746533,0.00006664481,0.0000017287421,0.00008877293,0.00016754198,0.88927066,0.0000064549045,0.0027520934,0.00029564463],"about_ca_topic_score_codex":0.000005391706,"about_ca_topic_score_gemma":0.0000056669605,"teacher_disagreement_score":0.6384757,"about_ca_system_score_codex":0.0000329015,"about_ca_system_score_gemma":0.00022035766,"threshold_uncertainty_score":0.79779345},"labels":[],"label_agreement":null},{"id":"W3091934681","doi":"10.1002/cpdd.871","title":"Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Trypanosoma species research and implications","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Bayer","keywords":"Bioequivalence; Cmax; Medicine; Dosing; Bioavailability; Pharmacology; Confidence interval; Pharmacokinetics; Internal medicine","score_opus":0.06803022149680939,"score_gpt":0.3917060144841638,"score_spread":0.32367579298735444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091934681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901762,0.0000766727,0.00007529653,0.00791691,0.00016385363,0.0014790806,0.000046831952,0.00002023066,0.000044922934],"genre_scores_gemma":[0.9941535,0.00016112061,0.0022329427,0.0029337655,0.00013783858,0.0001617122,0.0001489777,0.000020394977,0.00004977786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797916,0.00010777816,0.00089241605,0.00041165506,0.0002102505,0.00039873013],"domain_scores_gemma":[0.99851197,0.00043973164,0.00013156777,0.00011001039,0.00014380534,0.0006628918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013824317,0.00016356434,0.0005203006,0.00012720171,0.00004787107,0.000007991903,0.00012535507,0.00008235797,0.00011042074],"category_scores_gemma":[0.00045589238,0.00013558076,0.000043255633,0.000287955,0.00032288238,0.000059511876,0.00013407553,0.00041200014,0.0000094064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007902834,0.0021898632,0.97227824,0.0004268291,0.00015460524,0.0001586436,0.000389991,9.717015e-7,0.004999546,0.00004176013,0.0032961562,0.0081605865],"study_design_scores_gemma":[0.011459081,0.00027646462,0.97571117,0.00007953273,0.00007702888,8.026161e-7,0.000018266635,0.0005583867,0.0009771977,0.000008859201,0.010695873,0.00013734259],"about_ca_topic_score_codex":0.0000022796721,"about_ca_topic_score_gemma":0.0000026081473,"teacher_disagreement_score":0.008023244,"about_ca_system_score_codex":0.0000862367,"about_ca_system_score_gemma":0.00043836862,"threshold_uncertainty_score":0.5528823},"labels":[],"label_agreement":null},{"id":"W3095574760","doi":"10.1002/cpdd.884","title":"Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Bioequivalence; Medicine; Crossover study; Pharmacology; Type 2 diabetes; Pharmacokinetics; Confidence interval; Diabetes mellitus; Internal medicine; Endocrinology; Placebo","score_opus":0.05629632715691588,"score_gpt":0.35134043514486146,"score_spread":0.29504410798794556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095574760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98635197,0.00030510983,0.000113665476,0.010000479,0.000280628,0.0023316413,0.000019784638,0.00004497349,0.0005517512],"genre_scores_gemma":[0.98193276,0.0003418579,0.0059777964,0.010405678,0.000039695686,0.00030526647,0.00016074078,0.000041358577,0.0007948623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965392,0.00020216935,0.0014573052,0.0007198181,0.00034873156,0.00073278876],"domain_scores_gemma":[0.9978584,0.00063417404,0.00027001704,0.00020168198,0.00015333993,0.00088237756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012426071,0.00041033755,0.0011191191,0.0006206783,0.00006940143,0.000020309548,0.0002566283,0.00017003591,0.0001907422],"category_scores_gemma":[0.0002616874,0.0003401108,0.00006981022,0.0009015371,0.00022730134,0.00017265725,0.00023334096,0.000387018,0.000043309738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020893674,0.009821299,0.5740121,0.0027765287,0.005140921,0.0048447275,0.03014837,0.0011795247,0.008470632,0.00086676166,0.05046527,0.2913802],"study_design_scores_gemma":[0.10315658,0.011414297,0.6116032,0.0017007686,0.0018865262,0.00006551433,0.009129513,0.010700472,0.08372082,0.000432302,0.1631705,0.0030194805],"about_ca_topic_score_codex":0.001424064,"about_ca_topic_score_gemma":0.01046594,"teacher_disagreement_score":0.28836071,"about_ca_system_score_codex":0.00049355795,"about_ca_system_score_gemma":0.0009178395,"threshold_uncertainty_score":0.9999051},"labels":[],"label_agreement":null},{"id":"W3113925818","doi":"10.1002/cpdd.894","title":"Comparison of Steroidogenic Exposure Following the Administration of Repository Corticotropin Injection With a Synthetic ACTH<sub>1‐24</sub> Depot and Methylprednisolone in Healthy Subjects","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Adrenal Hormones and Disorders","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Depot; Prednisone; Methylprednisolone; Internal medicine; Pharmacodynamics; Subcutaneous injection; Pharmacokinetics; Adrenocorticotropic hormone; Endocrinology; Pharmacology; Hormone","score_opus":0.05146719463994026,"score_gpt":0.3778594674939645,"score_spread":0.3263922728540242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113925818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561805,0.001395796,0.00012283574,0.0018551138,0.00027107206,0.00069613947,6.9176366e-7,0.000013623752,0.000026668691],"genre_scores_gemma":[0.9985664,0.00015531474,0.0004494211,0.0007100989,0.00004138689,0.00005452728,0.000006628882,0.0000131333745,0.0000030845572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761873,0.00035136897,0.0012975583,0.00032286774,0.00020641767,0.00020305616],"domain_scores_gemma":[0.99878764,0.0005242668,0.00039785577,0.00010467739,0.000049852017,0.00013568113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039207464,0.00014930194,0.0006461662,0.00008006497,0.00004922879,0.0000036407662,0.00008468246,0.000119682096,0.0000033559306],"category_scores_gemma":[0.00014835576,0.00011085851,0.00007020837,0.00027277193,0.00019264307,0.00004423248,0.000059484166,0.0004255118,9.608232e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022453377,0.0018296954,0.8469501,0.00043607203,0.00037731905,0.00017974425,0.008880993,0.0002838229,0.1076362,0.000003417335,0.00027510253,0.010694161],"study_design_scores_gemma":[0.008025154,0.004799666,0.73834026,0.00019719562,0.0002823442,0.00005120114,0.0026293425,0.0010239715,0.24441144,0.000009346902,0.000042415068,0.00018769885],"about_ca_topic_score_codex":0.000021555823,"about_ca_topic_score_gemma":0.00020081307,"teacher_disagreement_score":0.13677524,"about_ca_system_score_codex":0.000059802296,"about_ca_system_score_gemma":0.00051469513,"threshold_uncertainty_score":0.4520679},"labels":[],"label_agreement":null},{"id":"W3119947423","doi":"10.1002/cpdd.901","title":"A Colon‐Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Warfarin; Bioequivalence; Pharmacokinetics; Clonazepam; Crossover study; Pharmacology; Cmax; Concomitant; Pharmacodynamics; Drug; Internal medicine; Placebo","score_opus":0.16681087861956184,"score_gpt":0.497394297777827,"score_spread":0.33058341915826517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119947423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97114944,0.003923571,0.000017553846,0.009427566,0.012697265,0.0017870978,0.00010395999,0.00008392451,0.0008096063],"genre_scores_gemma":[0.9591717,0.012283089,0.0010737248,0.024805635,0.00071096834,0.0005477852,0.00006338536,0.00007958112,0.0012641012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9876144,0.0055147037,0.0034144449,0.0012964297,0.000576121,0.0015839195],"domain_scores_gemma":[0.99169856,0.0059742536,0.0007728591,0.0004899555,0.00040270726,0.00066169025],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007374962,0.00073354604,0.0015812514,0.00041602214,0.00028652226,0.000024748091,0.0012189172,0.00070848485,0.00359998],"category_scores_gemma":[0.00079322443,0.00051845826,0.00034782817,0.0014566992,0.00087581476,0.00011161445,0.0008958895,0.00333075,0.00013398219],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043595567,0.026357757,0.32180706,0.001447844,0.0035832736,0.0069268253,0.016972689,0.007118163,0.34578693,0.0006311053,0.06103444,0.16473837],"study_design_scores_gemma":[0.018985672,0.00020911296,0.09094456,0.00006750616,0.0003794765,0.000051154173,0.00036837562,0.0023430842,0.5592449,0.00018846456,0.32639384,0.0008239147],"about_ca_topic_score_codex":0.00006366416,"about_ca_topic_score_gemma":0.0010502948,"teacher_disagreement_score":0.2653594,"about_ca_system_score_codex":0.00032663185,"about_ca_system_score_gemma":0.0026533867,"threshold_uncertainty_score":0.9997267},"labels":[],"label_agreement":null},{"id":"W3120034421","doi":"10.1002/cpdd.904","title":"Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"PTC Therapeutics","keywords":"Medicine; Pharmacokinetics; Tubulin; Pharmacology; Microtubule","score_opus":0.027670907593689963,"score_gpt":0.3555511339723538,"score_spread":0.3278802263786638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120034421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99750894,0.00064432516,0.00041967237,0.00027386972,0.0005982952,0.00030843052,0.00001154159,0.0000059458084,0.00022898597],"genre_scores_gemma":[0.9900283,0.0025560001,0.005574243,0.0013585538,0.0000947131,0.00005380832,0.000051572013,0.000025021618,0.0002577733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981228,0.00011444642,0.0007853314,0.00051982113,0.000117193784,0.00034039142],"domain_scores_gemma":[0.9993792,0.00008528004,0.00017999868,0.00014176195,0.0000921602,0.00012159187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060100405,0.00019565622,0.00040749923,0.0000755749,0.00003722989,0.0000058186138,0.00015209406,0.00012767757,0.00004303824],"category_scores_gemma":[0.00004033438,0.00019251902,0.00004900409,0.00019582247,0.00013990991,0.000004487369,0.00022678211,0.000274826,0.0000017615774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012546154,0.00065989036,0.010021635,0.00006704234,0.00017829693,0.00010686966,0.0004009986,0.00046413235,0.9745402,0.000027456723,0.00017653413,0.012102334],"study_design_scores_gemma":[0.008845712,0.00020234888,0.0153011205,0.00009646135,0.00003717258,0.00002956101,0.00018317442,0.00011958501,0.95083,0.000024977455,0.024025593,0.00030432432],"about_ca_topic_score_codex":0.000003954759,"about_ca_topic_score_gemma":0.00017385202,"teacher_disagreement_score":0.023849059,"about_ca_system_score_codex":0.000051734583,"about_ca_system_score_gemma":0.00055834383,"threshold_uncertainty_score":0.78506976},"labels":[],"label_agreement":null},{"id":"W3133802300","doi":"10.1002/cpdd.926","title":"Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Medicine; Telmisartan; Rosuvastatin; Ezetimibe; Pharmacokinetic interaction; Pharmacology; Pharmacokinetics; Internal medicine; Drug interaction; Statin; Blood pressure","score_opus":0.03683423971864972,"score_gpt":0.3937161031873667,"score_spread":0.356881863468717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133802300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923032,0.0010175508,0.00008735811,0.0025011487,0.0018138314,0.00053964416,0.0000013096718,0.000048496215,0.0016874557],"genre_scores_gemma":[0.9858953,0.0016114003,0.0042605754,0.0061810804,0.0005705511,0.0001243363,0.00003305637,0.000026929029,0.001296798],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99752504,0.00040296532,0.0009240429,0.00053869386,0.00024988677,0.0003593706],"domain_scores_gemma":[0.9989463,0.00026899166,0.00011760485,0.00018579641,0.00014029253,0.0003409886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014146913,0.00018467085,0.0005744532,0.00010176848,0.00007687169,0.0000141446535,0.00006653728,0.00012385043,0.0006704403],"category_scores_gemma":[0.00017599853,0.00017287103,0.00013097154,0.00023675188,0.000165243,0.000073356525,0.00014255785,0.0007229206,0.000055592354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006983206,0.0020844198,0.41282704,0.0005564319,0.0011141619,0.0032709055,0.0021239037,0.000051135346,0.005129379,0.00001440256,0.038839456,0.53329045],"study_design_scores_gemma":[0.007990864,0.00008554256,0.81289834,0.0001650301,0.00021911158,0.00026320404,0.00031737878,0.0005684847,0.02318748,0.000027567754,0.15399402,0.00028294895],"about_ca_topic_score_codex":0.000028098613,"about_ca_topic_score_gemma":0.00005755574,"teacher_disagreement_score":0.5330075,"about_ca_system_score_codex":0.00014017295,"about_ca_system_score_gemma":0.00054655893,"threshold_uncertainty_score":0.73408514},"labels":[],"label_agreement":null},{"id":"W3172814721","doi":"10.1002/cpdd.953","title":"Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacokinetics; Medicine; Drug; Tolerability; Pharmacology; Adverse effect; Drug interaction; Internal medicine","score_opus":0.16431230472200548,"score_gpt":0.4857998073438024,"score_spread":0.32148750262179693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172814721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930876,0.000095630734,0.000007734441,0.0031275651,0.0018628588,0.001603144,0.000042251766,0.0000180364,0.00015520165],"genre_scores_gemma":[0.997281,0.0003941,0.00009198459,0.0017724066,0.00009296933,0.0002476196,0.000011987197,0.000019535137,0.000088360626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9916118,0.0045828074,0.0019643274,0.0008333515,0.00053915917,0.00046859114],"domain_scores_gemma":[0.9795901,0.019376505,0.0004736524,0.00026655613,0.00014485256,0.00014834203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029101332,0.00025153346,0.0007431237,0.00023674582,0.0000896487,0.000014730697,0.0005556028,0.00008031434,0.00017848227],"category_scores_gemma":[0.003168002,0.00019207483,0.00010294612,0.0007165702,0.00042344775,0.00008947873,0.00033743447,0.001152427,0.000029416931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086165845,0.14841276,0.09183491,0.00053309754,0.00086211856,0.0045095845,0.09033997,0.0014131352,0.4210906,0.0001476427,0.02716096,0.12752935],"study_design_scores_gemma":[0.028048804,0.00045910067,0.06346938,0.00016060972,0.000044837947,0.0000016099323,0.002485609,0.00082171895,0.90246713,0.000054556025,0.0017763796,0.00021028418],"about_ca_topic_score_codex":0.00018808371,"about_ca_topic_score_gemma":0.00046006942,"teacher_disagreement_score":0.4813765,"about_ca_system_score_codex":0.00015745022,"about_ca_system_score_gemma":0.00056675577,"threshold_uncertainty_score":0.78325844},"labels":[],"label_agreement":null},{"id":"W3200515041","doi":"10.1002/cpdd.1020","title":"Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH<sub>1‐24</sub> Depot and Methylprednisolone in Healthy Subjects","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Adrenal Hormones and Disorders","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Depot; Medicine; Pharmacodynamics; Adrenocorticotropic hormone; Pharmacokinetics; Methylprednisolone; Internal medicine; Endocrinology; Corticosteroid; Pharmacology; Hormone","score_opus":0.025231091828969862,"score_gpt":0.34140215033178634,"score_spread":0.31617105850281646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200515041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994293,0.0031948413,0.00012377786,0.0009997599,0.00063899957,0.0006085321,0.0000031101831,0.000028892384,0.00010909333],"genre_scores_gemma":[0.9919766,0.0047389567,0.0017255421,0.001349745,0.00006692073,0.0000611526,0.00002344442,0.000028751265,0.000028886663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970416,0.0004090831,0.0013243579,0.0005988275,0.0002302598,0.00039589324],"domain_scores_gemma":[0.9984842,0.00061830686,0.0003135881,0.00014012888,0.00014806772,0.0002957217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043395453,0.0002610242,0.0008486836,0.00021260521,0.00007048041,0.0000084941385,0.0000762868,0.00015501617,0.0000144472615],"category_scores_gemma":[0.00010349535,0.0002431556,0.00005097669,0.00040368462,0.0004168036,0.00006296795,0.00015033799,0.0006674669,0.0000017030848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01865319,0.0054084957,0.6483202,0.0013257626,0.00081705465,0.0025671455,0.0032449795,0.0009189277,0.28071126,0.000014688801,0.0012420103,0.0367763],"study_design_scores_gemma":[0.027994461,0.0011764354,0.6646044,0.00040785462,0.0005794731,0.00085447286,0.0010573668,0.00894984,0.2932252,0.000046966605,0.00051905116,0.0005844718],"about_ca_topic_score_codex":0.000041955183,"about_ca_topic_score_gemma":0.00023741444,"teacher_disagreement_score":0.03619183,"about_ca_system_score_codex":0.00014167938,"about_ca_system_score_gemma":0.0006965545,"threshold_uncertainty_score":0.9915598},"labels":[],"label_agreement":null},{"id":"W3215986232","doi":"10.1002/cpdd.1043","title":"The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P‐Glycoprotein Substrate Digoxin in Healthy Volunteers","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Digoxin; Medicine; Pharmacokinetics; Pharmacology; Tolerability; Oral administration; Crossover study; Internal medicine; Placebo; Adverse effect; Heart failure","score_opus":0.07222058166040611,"score_gpt":0.4252310117062345,"score_spread":0.3530104300458284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215986232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309,0.0003113678,0.0000024648145,0.004657657,0.00040692528,0.0011532758,0.0000085633865,0.000006993287,0.0003627855],"genre_scores_gemma":[0.99844503,0.0003803249,0.00017549723,0.0006249458,0.00005082176,0.0001133063,0.000013499206,0.000016962322,0.00017958459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959368,0.0012591258,0.0016452962,0.00032886022,0.0004347355,0.00039516148],"domain_scores_gemma":[0.9964972,0.0026367072,0.00031585761,0.00024945778,0.00017265332,0.00012808379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00426071,0.00019040784,0.00072841777,0.00013539166,0.000059463466,0.000007654609,0.0002641828,0.00013847159,0.00025057205],"category_scores_gemma":[0.0006159313,0.00011868299,0.00014433803,0.00053587154,0.00058624457,0.000030169003,0.0001299012,0.00079990673,0.00001178522],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08688839,0.008793138,0.31600118,0.0015942117,0.001015525,0.00092958554,0.0025162247,0.00024770817,0.40618297,0.00019964062,0.008461143,0.16717029],"study_design_scores_gemma":[0.0104748765,0.0028843344,0.1268987,0.00020474746,0.00006546535,0.0000086098535,0.00013467802,0.0004389905,0.85073465,0.00002720613,0.007992896,0.00013480609],"about_ca_topic_score_codex":0.00008424197,"about_ca_topic_score_gemma":0.0006601622,"teacher_disagreement_score":0.4445517,"about_ca_system_score_codex":0.00016048334,"about_ca_system_score_gemma":0.0011591226,"threshold_uncertainty_score":0.4839752},"labels":[],"label_agreement":null},{"id":"W4220822477","doi":"10.1002/cpdd.1089","title":"Effect of Colonic Absorption on the Pharmacokinetic Properties of Delayed‐Release and Extended‐Release Methylphenidate: In Vivo, In Vitro, and Modeling Evaluations","year":2022,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viron Therapeutics (Canada)","funders":"","keywords":"Pharmacokinetics; Methylphenidate; Bioavailability; Pharmacology; Absorption (acoustics); Morning; Medicine; Crossover study; In vivo; Gastrointestinal tract; Small intestine; Evening; Internal medicine; Attention deficit hyperactivity disorder; Biology; Materials science; Placebo; Psychiatry; Pathology","score_opus":0.0722415416888,"score_gpt":0.4134766494053294,"score_spread":0.34123510771652943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220822477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540347,0.0010110846,0.000015300242,0.0017558668,0.00019395883,0.0015780502,0.0000066097587,0.000010635211,0.00002502392],"genre_scores_gemma":[0.9982042,0.0003632442,0.000093798786,0.00061856216,0.000016196942,0.00062838313,0.000008529502,0.000017636508,0.000049472816],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9965731,0.0014430173,0.0010532485,0.00038052798,0.00031749468,0.00023260355],"domain_scores_gemma":[0.99819934,0.0013172205,0.00021283717,0.0001294316,0.00006561511,0.0000755668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040864157,0.00017794002,0.0005626304,0.00033523937,0.00007271282,0.0000031289485,0.00010951475,0.000069453716,0.000287213],"category_scores_gemma":[0.00052285043,0.00013938265,0.000057217625,0.00037063932,0.00020063476,0.00005443636,0.0002054638,0.0007874417,0.0000028331472],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030146027,0.008339152,0.06332638,0.0009139692,0.00052324776,0.00014573887,0.006261289,0.074032135,0.7647265,0.00003488524,0.00039600563,0.051154647],"study_design_scores_gemma":[0.036803808,0.0022316335,0.06473717,0.00039324161,0.00074839196,0.000053137956,0.0027509679,0.6486887,0.24259749,0.00012970471,0.00027510687,0.00059065234],"about_ca_topic_score_codex":0.00008077661,"about_ca_topic_score_gemma":0.00003647065,"teacher_disagreement_score":0.57465655,"about_ca_system_score_codex":0.00017189764,"about_ca_system_score_gemma":0.00030520133,"threshold_uncertainty_score":0.56838596},"labels":[],"label_agreement":null},{"id":"W4293367557","doi":"10.1002/cpdd.1153","title":"Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors","year":2022,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Bioavailability; Pharmacokinetics; Medicine; Pharmacology; Tolerability; Bioequivalence; Chemistry; Adverse effect","score_opus":0.23958492077186636,"score_gpt":0.4805594073694024,"score_spread":0.24097448659753604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293367557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925364,0.000260457,0.00008260399,0.0059808744,0.00043316407,0.003771568,0.0000040674818,0.000053083724,0.0001605279],"genre_scores_gemma":[0.992294,0.00015850167,0.0037025148,0.001327247,0.00013689342,0.0011598368,0.000023013972,0.00002041911,0.0011775728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967754,0.00052640977,0.00090371876,0.00074159406,0.0006028781,0.00045003177],"domain_scores_gemma":[0.99748254,0.0015986225,0.00020413923,0.0001998528,0.00016290843,0.00035196816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003150539,0.0002271638,0.0005456663,0.00019710381,0.0002532387,0.00001542006,0.0001636072,0.00009876618,0.00019728979],"category_scores_gemma":[0.0007162066,0.00018430222,0.000043104228,0.0005299061,0.0003590231,0.00016443996,0.00060847925,0.0007143082,0.000018881557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01829172,0.0035749367,0.8743407,0.0016316709,0.0016356567,0.0011271613,0.031220987,0.000482438,0.004071472,0.00026112294,0.0348546,0.028507523],"study_design_scores_gemma":[0.123746656,0.008438784,0.451172,0.0010425778,0.0007195319,0.0005635032,0.016031176,0.0044990554,0.22506566,0.0013428786,0.16526996,0.002108238],"about_ca_topic_score_codex":0.000062886895,"about_ca_topic_score_gemma":0.00008921944,"teacher_disagreement_score":0.42316872,"about_ca_system_score_codex":0.006628006,"about_ca_system_score_gemma":0.0103206495,"threshold_uncertainty_score":0.99718535},"labels":[],"label_agreement":null},{"id":"W4318332812","doi":"10.1002/cpdd.1210","title":"A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers","year":2023,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Salix Pharmaceuticals; Bausch Health; Mitsubishi Tanabe Pharma Corporation","keywords":"Medicine; Placebo; Moxifloxacin; Crossover study; Dosing; QT interval; Anesthesia; Pharmacokinetics; Adverse effect; Confidence interval; Oral administration; Internal medicine; Antibiotics","score_opus":0.039471458823368014,"score_gpt":0.36662950945268197,"score_spread":0.32715805062931397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318332812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99129236,0.00035066652,0.0021320644,0.00083263934,0.00028433715,0.005052113,0.000011965703,0.00001376864,0.000030106852],"genre_scores_gemma":[0.9958697,0.00022407697,0.0009974691,0.0017529648,0.00011105462,0.00092418597,0.000032710588,0.000024479783,0.000063346466],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963217,0.0015131693,0.00094414694,0.0005837093,0.00020896585,0.00042834796],"domain_scores_gemma":[0.9982727,0.0010513432,0.00019062632,0.00019208198,0.0001407163,0.00015250668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004756499,0.00026314857,0.0009861536,0.00011326563,0.000111631234,0.000016052656,0.0002469428,0.00009061387,0.0000053643885],"category_scores_gemma":[0.00011166919,0.00016837941,0.000070892915,0.00038499516,0.0003372442,0.0000075194507,0.00015114449,0.0003168467,0.0000040338873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92819387,0.00048065247,0.043024953,0.000019459923,0.0007688079,0.000042811986,0.005087138,0.020580156,0.000751146,0.0000067109254,0.0007862484,0.0002580269],"study_design_scores_gemma":[0.88082284,0.00089307566,0.109819025,0.00008146443,0.00029479698,0.000007815026,0.0027663694,0.0009103025,0.002436608,0.0000064288483,0.0014722554,0.00048900914],"about_ca_topic_score_codex":0.00017989257,"about_ca_topic_score_gemma":0.00044385565,"teacher_disagreement_score":0.066794075,"about_ca_system_score_codex":0.00003539544,"about_ca_system_score_gemma":0.00047545636,"threshold_uncertainty_score":0.68663126},"labels":[],"label_agreement":null},{"id":"W4384126864","doi":"10.1002/cpdd.1300","title":"Comparative Bioavailability of Two Daily Subcutaneous Doses Versus a Single Dose of Intramuscular and Vaginal Progesterone Formulations in Healthy Postmenopausal Females","year":2023,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Ovarian function and disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Bioavailability; Luteal phase; Crossover study; Pharmacokinetics; Estrous cycle; Internal medicine; Hormone; Pharmacology","score_opus":0.13826118681176483,"score_gpt":0.44333469550781796,"score_spread":0.3050735086960531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384126864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962629,0.0001926428,0.000009886182,0.001890942,0.0005501701,0.00083383295,0.0000058321425,0.000032898948,0.00022086805],"genre_scores_gemma":[0.9975965,0.0000778101,0.0018209106,0.0003407134,0.00002757297,0.000049623493,0.000043695443,0.000008458123,0.0000346953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790674,0.0002573025,0.001086018,0.00033410787,0.00015819976,0.00025762277],"domain_scores_gemma":[0.99849045,0.00096338766,0.0001870275,0.000118768396,0.000102677295,0.0001377064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009132476,0.0001426255,0.0006038935,0.00026603072,0.000035150813,0.0000031291543,0.00006942246,0.00009004477,0.00009669445],"category_scores_gemma":[0.00016968646,0.00013287077,0.00003862824,0.0005126642,0.00043465305,0.0000497607,0.00008926984,0.00027478358,0.000017325512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04319278,0.009903808,0.9070687,0.0007637176,0.0006206834,0.00030888608,0.012593802,0.00035486952,0.010559107,0.00024910524,0.0016244026,0.012760129],"study_design_scores_gemma":[0.026501516,0.0028781397,0.96496886,0.00007935639,0.00009924348,0.000017839098,0.0012688985,0.0005359109,0.002205782,0.00015574666,0.0011037329,0.0001849691],"about_ca_topic_score_codex":0.00004343729,"about_ca_topic_score_gemma":0.0003409808,"teacher_disagreement_score":0.057900153,"about_ca_system_score_codex":0.00011253551,"about_ca_system_score_gemma":0.0004962292,"threshold_uncertainty_score":0.54183125},"labels":[],"label_agreement":null},{"id":"W4390599050","doi":"10.1002/cpdd.1364","title":"Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CYP3A; CYP3A4; Tacrolimus; Pharmacology; Medicine; Pharmacokinetics; Drug interaction; CYP3A5; Calcineurin; Crossover study; P-glycoprotein; Pharmacokinetic interaction; Cmax; Inducer; Cytochrome P450; Internal medicine; Metabolism; Chemistry; Transplantation; Antibiotics; Biochemistry","score_opus":0.07446660461163242,"score_gpt":0.4725914293935504,"score_spread":0.398124824781918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390599050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97961926,0.0011495036,0.0000473996,0.0038200095,0.011081115,0.0027824382,0.00015321017,0.00021617256,0.0011308846],"genre_scores_gemma":[0.99029404,0.0007139752,0.00026887885,0.0050304933,0.0010720819,0.0008136334,0.00012645782,0.000097020726,0.0015834285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917203,0.0029780432,0.0021939573,0.0014250589,0.00052345026,0.0011591766],"domain_scores_gemma":[0.9922435,0.005710079,0.00038138308,0.00039334636,0.00028100525,0.0009906705],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006765561,0.0007785872,0.0012551952,0.00075293536,0.00028279415,0.00003967042,0.00072289596,0.0003274515,0.0023024692],"category_scores_gemma":[0.00038715478,0.0006514548,0.00033363744,0.0010602366,0.00032720144,0.00024757732,0.0003756463,0.0029700682,0.00089721906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06409511,0.010847031,0.13394354,0.002711745,0.004580063,0.002281061,0.014467175,0.034096945,0.0519399,0.0003650859,0.25444964,0.4262227],"study_design_scores_gemma":[0.01234826,0.00101259,0.037799653,0.00032121225,0.0011476378,0.000033148026,0.000111958565,0.01123,0.42862538,0.00009721654,0.50597143,0.0013015326],"about_ca_topic_score_codex":0.000030614898,"about_ca_topic_score_gemma":0.00023936798,"teacher_disagreement_score":0.42492118,"about_ca_system_score_codex":0.00042490946,"about_ca_system_score_gemma":0.00080368633,"threshold_uncertainty_score":0.9998807},"labels":[],"label_agreement":null},{"id":"W4391362198","doi":"10.1002/cpdd.1381","title":"Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths?","year":2024,"lang":"en","type":"letter","venue":"Clinical Pharmacology in Drug Development","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Nalmefene; Nasal administration; Opioid; Opioid overdose; Naltrexone; Anesthesia; Intensive care medicine; Narcotic antagonists; Pharmacology; (+)-Naloxone; Internal medicine","score_opus":0.04034816234880309,"score_gpt":0.40442199946430896,"score_spread":0.3640738371155059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391362198","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2917353,0.001752384,0.0000015558433,0.6949995,0.0076695336,0.0016691918,0.000056924313,0.00008590707,0.002029705],"genre_scores_gemma":[0.07102055,0.0039256117,0.0019653721,0.89909494,0.006202541,0.0009635377,0.0009146366,0.00024325815,0.01566958],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99455786,0.00054879277,0.0023550505,0.001088257,0.00064504007,0.000805023],"domain_scores_gemma":[0.997262,0.0013684154,0.00040789423,0.00059903786,0.00017020144,0.00019245122],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011637944,0.0006819043,0.0015604332,0.00023901818,0.00007641684,0.0000182028,0.00061405706,0.0010326182,0.0014451576],"category_scores_gemma":[0.00013526701,0.00047782145,0.00044404992,0.00045129648,0.0005989401,0.000029857572,0.0004182913,0.0048321486,0.00052175554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026198296,0.000878676,0.010127723,0.000903112,0.0018104451,0.0030480204,0.002131373,0.0000026508094,0.000030431938,0.000012621147,0.97721934,0.0035736107],"study_design_scores_gemma":[0.0040121446,0.00010074255,0.021454645,0.0006930228,0.001303764,0.00013139645,0.000121827514,0.000019062485,0.0017666625,0.00043301083,0.9694657,0.00049805804],"about_ca_topic_score_codex":0.00014228675,"about_ca_topic_score_gemma":0.000035517,"teacher_disagreement_score":0.22071475,"about_ca_system_score_codex":0.0007061982,"about_ca_system_score_gemma":0.0034504107,"threshold_uncertainty_score":0.99976736},"labels":[],"label_agreement":null},{"id":"W4391607838","doi":"10.1002/cpdd.1383","title":"Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast‐Acting, Nondihydropyridine Calcium Channel Blocker","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada); Vertex Pharmaceuticals (Canada); Cégep de Saint-Laurent","funders":"","keywords":"Medicine; Pharmacodynamics; Calcium channel blocker; Pharmacokinetics; Nasal administration; Pharmacology; Calcium channel; Anesthesia; Calcium; Internal medicine","score_opus":0.038452549964604524,"score_gpt":0.3985359675126638,"score_spread":0.3600834175480593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391607838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908066,0.0019418646,0.00021690696,0.0021164215,0.0036073076,0.00068418065,0.00002055228,0.00012400514,0.0004821673],"genre_scores_gemma":[0.9921371,0.0019227972,0.0013543736,0.002715825,0.0010317803,0.00006852296,0.0000797564,0.000058910744,0.00063097203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99662554,0.00033600398,0.0013896867,0.0008070783,0.00024045484,0.00060124625],"domain_scores_gemma":[0.9984516,0.0006382984,0.00017015317,0.00019851474,0.00012154517,0.0004199014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012462062,0.00038164918,0.0009538569,0.00039034802,0.00008041597,0.000014226699,0.00017788909,0.0002903482,0.00024296394],"category_scores_gemma":[0.00007750797,0.00035079435,0.0001874544,0.00046089644,0.000505649,0.00011336662,0.00019181459,0.001371136,0.000036635745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015111696,0.008720546,0.023099545,0.0043971166,0.007748026,0.020043945,0.0140121095,0.0013132788,0.5900853,0.00026998107,0.06317268,0.25202572],"study_design_scores_gemma":[0.044103768,0.0044052578,0.09620896,0.0016501299,0.0045642806,0.0028562066,0.0009909456,0.18797949,0.5165746,0.00047834223,0.13660195,0.0035860643],"about_ca_topic_score_codex":0.000009566716,"about_ca_topic_score_gemma":0.000009461972,"teacher_disagreement_score":0.24843967,"about_ca_system_score_codex":0.00012767315,"about_ca_system_score_gemma":0.00070069055,"threshold_uncertainty_score":0.9998944},"labels":[],"label_agreement":null},{"id":"W4391745346","doi":"10.1002/cpdd.1379","title":"Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Pfizer","keywords":"Pharmacokinetics; Medicine; Pharmacodynamics; Dosing; Adverse effect; Pharmacology; Discontinuation; Internal medicine; Gastroenterology","score_opus":0.05411766612786526,"score_gpt":0.4104809408775827,"score_spread":0.3563632747497174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391745346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712616,0.025340233,0.000055461194,0.00052266323,0.0023821446,0.00036718286,0.000012466129,0.000016947566,0.00004127973],"genre_scores_gemma":[0.974553,0.022869926,0.0013918766,0.0007230114,0.0003410446,0.000024841747,0.000027297214,0.00002563792,0.000043394306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770623,0.00024731064,0.00095237215,0.00062246126,0.00011267415,0.0003589671],"domain_scores_gemma":[0.9991188,0.0004828053,0.00011115371,0.000090029906,0.000057554476,0.0001396232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014576175,0.00022865513,0.00046668772,0.0001990147,0.000054521675,0.000010958499,0.00014218067,0.0001475817,0.0000128298325],"category_scores_gemma":[0.00021453227,0.00022246405,0.000051303177,0.0002069292,0.0003378262,0.000011514915,0.00031614865,0.00036954117,0.0000018131346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010944479,0.0020196934,0.15983152,0.0029895937,0.0013315345,0.00033170075,0.009169551,0.0011392778,0.6446733,0.00008333303,0.0062255133,0.16126052],"study_design_scores_gemma":[0.063491166,0.001744893,0.13236512,0.0019687118,0.0005292941,0.00013546117,0.004239673,0.036102198,0.5266338,0.00025232817,0.22972983,0.0028075175],"about_ca_topic_score_codex":0.000011643135,"about_ca_topic_score_gemma":0.00007700935,"teacher_disagreement_score":0.22350432,"about_ca_system_score_codex":0.000050974115,"about_ca_system_score_gemma":0.0001562839,"threshold_uncertainty_score":0.90718204},"labels":[],"label_agreement":null},{"id":"W4392648981","doi":"10.1002/cpdd.1395","title":"Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Réseau Québécois de Recherche sur les Médicaments","keywords":"NONMEM; Tobramycin; Medicine; Population; Pharmacokinetics; Antibacterial agent; Dosing; Gentamicin; Statistics; Antibiotics; Pharmacology; Mathematics; Microbiology; Biology","score_opus":0.1347633873784191,"score_gpt":0.4706056355172811,"score_spread":0.335842248138862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392648981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239767,0.0019490453,0.0009882222,0.00028896471,0.0027624648,0.0013613956,0.000005576687,0.00003427461,0.00021238065],"genre_scores_gemma":[0.9938043,0.00023993543,0.005437137,0.0001466432,0.00019395923,0.000032971413,0.00009522646,0.00003588017,0.0000139879585],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9961931,0.00053205213,0.0014618441,0.0005569496,0.0009612646,0.00029477035],"domain_scores_gemma":[0.99867463,0.00041314244,0.00023302807,0.00016208799,0.0003253934,0.0001917289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061575486,0.0002500136,0.0005805128,0.00034976492,0.00004588436,0.000017018823,0.00013353505,0.00014746664,0.00030813663],"category_scores_gemma":[0.00016182233,0.00024067466,0.00012391989,0.0002805039,0.00011763339,0.00018810313,0.00011117338,0.00035008654,0.000005649358],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030400585,0.0021911056,0.0583175,0.0008030864,0.001261263,0.00009638274,0.003896202,0.038048726,0.12432139,0.00006099457,0.00035773305,0.76760554],"study_design_scores_gemma":[0.011691896,0.00026646035,0.15026297,0.00041174024,0.002577058,0.000011535002,0.00009611315,0.8112014,0.022458944,0.00076692353,0.000040284853,0.00021470837],"about_ca_topic_score_codex":0.00005113689,"about_ca_topic_score_gemma":0.000017241226,"teacher_disagreement_score":0.77315265,"about_ca_system_score_codex":0.0002791639,"about_ca_system_score_gemma":0.0005633375,"threshold_uncertainty_score":0.9814428},"labels":[],"label_agreement":null},{"id":"W4400593447","doi":"10.1002/cpdd.1436","title":"Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Crossover study; Placebo; Internal medicine; Tolerability; Area under the curve; Oral administration; Gastroenterology; Randomized controlled trial; Pharmacology; Adverse effect; Pathology","score_opus":0.03734745860357723,"score_gpt":0.4049165509674602,"score_spread":0.36756909236388297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400593447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868215,0.004940617,0.0000021295657,0.0045525017,0.00095806987,0.0006449785,0.0000039125134,0.00003454744,0.00018111037],"genre_scores_gemma":[0.9969308,0.0017021514,0.00012444233,0.0008991667,0.00011419237,0.000105268344,0.000010236571,0.000017403192,0.000096331394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979258,0.0002936264,0.0008920897,0.0004012269,0.00011423994,0.00037299987],"domain_scores_gemma":[0.9989367,0.00064125354,0.00005776403,0.000074570315,0.000021162854,0.00026854427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013129048,0.00015960778,0.0005384576,0.00026174783,0.00003725911,0.000007807288,0.000051373998,0.00012700447,0.000112260044],"category_scores_gemma":[0.000088479064,0.00013294589,0.000052646315,0.0002680832,0.00022012951,0.000043881308,0.000083276034,0.00065113977,0.00001468706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021995688,0.0023632802,0.7272623,0.005177748,0.002039493,0.0045335945,0.030302143,0.000071892944,0.007134692,0.00008694963,0.009766982,0.20906135],"study_design_scores_gemma":[0.014500643,0.001231303,0.97008467,0.0012575523,0.00046185844,0.0003027454,0.0002658416,0.0036197226,0.0036019108,0.00008514622,0.0042638266,0.00032481118],"about_ca_topic_score_codex":0.000022175176,"about_ca_topic_score_gemma":0.0000528864,"teacher_disagreement_score":0.24282233,"about_ca_system_score_codex":0.00007550459,"about_ca_system_score_gemma":0.000254125,"threshold_uncertainty_score":0.5421376},"labels":[],"label_agreement":null},{"id":"W4406772778","doi":"10.1002/cpdd.1509","title":"Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Kruppel-like factors research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Gilead Sciences","keywords":"Medicine; Moxifloxacin; QT interval; Placebo; Adverse effect; Dosing; Crossover study; Confidence interval; Pharmacology; Discontinuation; Pharmacokinetics; Anesthesia; Internal medicine; Antibiotics","score_opus":0.03976649950671286,"score_gpt":0.4610328291571056,"score_spread":0.42126632965039273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406772778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513686,0.00018709169,0.000010011654,0.00025577343,0.0015696794,0.0016713429,0.0000040115942,0.000003902619,0.0011613015],"genre_scores_gemma":[0.9990238,0.000030338007,0.00003983242,0.000114963856,0.00007009304,0.00019098636,0.00001614683,0.000008699327,0.0005051238],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99457836,0.0035227507,0.00082617323,0.0003864331,0.0005021275,0.00018415878],"domain_scores_gemma":[0.9986442,0.00043929525,0.00019992632,0.00035027656,0.00032983097,0.000036507667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008697181,0.00013371086,0.00035194468,0.0000870987,0.000051502204,0.000003469816,0.00037391955,0.00015060508,0.000032235475],"category_scores_gemma":[0.0019351363,0.00009621555,0.00011775869,0.0003283554,0.0001662203,0.0000023813238,0.00037570152,0.00027500468,0.000004130683],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006527028,0.0010373502,0.9327579,0.00005481502,0.00066167687,0.0000017669456,0.0002732036,0.00051604596,0.044194356,0.0000050723156,0.00661388,0.01323123],"study_design_scores_gemma":[0.002626244,0.00042357823,0.48534745,0.000027590582,0.00012551597,1.720704e-7,0.000056895376,0.000061585146,0.50851125,0.000012085865,0.002733054,0.00007459089],"about_ca_topic_score_codex":0.00001472217,"about_ca_topic_score_gemma":0.00002443974,"teacher_disagreement_score":0.46431687,"about_ca_system_score_codex":0.000092041584,"about_ca_system_score_gemma":0.000867002,"threshold_uncertainty_score":0.39235562},"labels":[],"label_agreement":null},{"id":"W4409504657","doi":"10.1002/cpdd.1534","title":"A Phase 1C, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DM199 Administered Intravenously with a Polyvinyl Chloride Bag in Adult Healthy Subjects and Adults Recently Taking Angiotensin‐Converting Enzyme Inhibitors","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; Adverse effect; Dosing; Context (archaeology); Anesthesia; Pharmacology; Internal medicine","score_opus":0.06909627066100327,"score_gpt":0.42693431326928105,"score_spread":0.3578380426082778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409504657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836317,0.0005939951,0.000012103697,0.010430963,0.00086780754,0.0043571503,0.000006184138,0.00003143335,0.00006867851],"genre_scores_gemma":[0.99215215,0.00023303498,0.001095558,0.006144169,0.0001421945,0.00013209766,0.000015134571,0.00003181994,0.00005383704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523026,0.00067875057,0.0022382834,0.0009095737,0.00033943326,0.000603701],"domain_scores_gemma":[0.9972284,0.0014304984,0.0004529266,0.00027320028,0.00028879114,0.00032621503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003735752,0.00037878938,0.0011378966,0.0003547693,0.00020469535,0.000044893768,0.00030784964,0.0001183506,0.0000307479],"category_scores_gemma":[0.0008486823,0.0002990244,0.0000449313,0.00085000636,0.00029869232,0.00011997739,0.00070777244,0.0005732475,0.0000017831458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056231268,0.02003417,0.6538818,0.0005851344,0.0006946517,0.00034733833,0.042117752,0.0000415736,0.004435994,0.00002210529,0.0008107312,0.22079748],"study_design_scores_gemma":[0.1491501,0.0094066495,0.765847,0.0037536283,0.0007676435,0.00007561907,0.0074054524,0.0036422953,0.057374205,0.00005957919,0.001607502,0.0009102746],"about_ca_topic_score_codex":0.00053103257,"about_ca_topic_score_gemma":0.0023989913,"teacher_disagreement_score":0.21988721,"about_ca_system_score_codex":0.00030175125,"about_ca_system_score_gemma":0.0009414412,"threshold_uncertainty_score":0.9999462},"labels":[],"label_agreement":null},{"id":"W4409765779","doi":"10.1002/cpdd.1540","title":"Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"","keywords":"NS5A; Medicine; Pharmacology; Drug; Adverse effect; Hepatitis C virus; NS5B; Combination therapy; Chronic hepatitis; Hepacivirus; Virus; Virology","score_opus":0.217051315865395,"score_gpt":0.6195449109795277,"score_spread":0.4024935951141327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409765779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577,0.00004096812,0.000043290293,0.00041457458,0.0003710559,0.0031781907,0.000015851558,0.000008472171,0.00015760658],"genre_scores_gemma":[0.99856144,0.00007991244,0.0009052542,0.000103807,0.000056938286,0.00023565357,0.000038288483,0.000011304314,0.000007397294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99040794,0.0045552542,0.0033972226,0.0005733296,0.00073082116,0.0003354305],"domain_scores_gemma":[0.99608123,0.0024288748,0.0005869213,0.00025475767,0.0004387897,0.00020941698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021367153,0.00017029459,0.0012120599,0.0004981431,0.000028790952,0.0000034677437,0.00015165086,0.00016782698,0.000033234868],"category_scores_gemma":[0.0013617962,0.00014307571,0.00005908294,0.000491508,0.00033077752,0.00009208913,0.0001663863,0.0008013693,9.75065e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014705219,0.01055432,0.82222575,0.00020933094,0.0005211825,0.000022734253,0.00070080865,0.00004961277,0.0003926499,0.0000011045537,0.00007584112,0.15054145],"study_design_scores_gemma":[0.06641269,0.016268598,0.90806574,0.00028874437,0.0004451836,5.747779e-7,0.00029762776,0.004742673,0.0033246328,0.00001716421,0.000046912635,0.00008946533],"about_ca_topic_score_codex":0.00013444053,"about_ca_topic_score_gemma":0.0007329248,"teacher_disagreement_score":0.15045199,"about_ca_system_score_codex":0.0002532168,"about_ca_system_score_gemma":0.0023767413,"threshold_uncertainty_score":0.7405471},"labels":[],"label_agreement":null},{"id":"W4409956934","doi":"10.1002/cpdd.1538","title":"A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare","keywords":"Medicine; Tolerability; Dosing; Pharmacokinetics; Adverse effect; Pharmacology; Regimen; Internal medicine","score_opus":0.0388030569631078,"score_gpt":0.4428926940845356,"score_spread":0.40408963712142776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409956934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990444,0.00029698203,0.00033984543,0.0024755246,0.0006102137,0.0055321166,0.0000038464295,0.00003973336,0.00025774245],"genre_scores_gemma":[0.9938616,0.00026754383,0.004206635,0.0003719013,0.00006357885,0.00040610728,0.00008682676,0.000017046974,0.0007187451],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939614,0.0012756968,0.0032714016,0.0007354619,0.00034959635,0.00040647268],"domain_scores_gemma":[0.9968377,0.0020345207,0.0005054463,0.00018874799,0.00027762138,0.00015598575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0064850943,0.00034346135,0.0017213337,0.00032392147,0.0001022831,0.000011735475,0.00012884875,0.00014277853,0.00011614512],"category_scores_gemma":[0.0010398405,0.00029354467,0.00010871119,0.0005218897,0.00022183332,0.00011280863,0.00015434778,0.00054096576,0.0000060446137],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13356392,0.0069603543,0.7943307,0.00027007962,0.0007218755,0.00007381995,0.009340967,0.00018428535,0.0001366565,0.000019470062,0.00021995862,0.05417787],"study_design_scores_gemma":[0.68772066,0.0002249863,0.29170957,0.000687558,0.00062555633,0.0000035437204,0.00086892245,0.014794653,0.0027338522,0.00012962747,0.00020023582,0.0003008282],"about_ca_topic_score_codex":0.00007481312,"about_ca_topic_score_gemma":0.00020532556,"teacher_disagreement_score":0.5541567,"about_ca_system_score_codex":0.00041902342,"about_ca_system_score_gemma":0.0009219371,"threshold_uncertainty_score":0.99995166},"labels":[],"label_agreement":null},{"id":"W4413114117","doi":"10.1002/cpdd.1583","title":"Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Coronavirus disease 2019 (COVID-19); Pharmacokinetics; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Monoclonal antibody; 2019-20 coronavirus outbreak; Pharmacology; Antibody; Immunology; Adverse effect; Internal medicine; Infectious disease (medical specialty); Outbreak; Disease","score_opus":0.05256922252441759,"score_gpt":0.4732816387254207,"score_spread":0.4207124162010031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413114117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876119,0.0006319882,0.000036886777,0.007927519,0.0013782149,0.0015088755,0.0000041393782,0.00003112344,0.0008693778],"genre_scores_gemma":[0.96495366,0.0002024414,0.00033164115,0.03429744,0.0000893576,0.00007412441,0.000009566293,0.00001892112,0.00002283745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956741,0.0007271751,0.0019756677,0.00066737,0.00039994082,0.0005557624],"domain_scores_gemma":[0.9973045,0.0018613883,0.00028344893,0.00025510477,0.00022932178,0.00006624656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033077023,0.0002912697,0.00085031916,0.00037033815,0.00012962279,0.000014852174,0.00039526605,0.00021682617,0.000016270942],"category_scores_gemma":[0.0007711737,0.00022890586,0.0001324635,0.0010062439,0.00044443578,0.00009280511,0.0006240891,0.001366497,0.0000067463216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003992257,0.0021949657,0.95084,0.0007690903,0.00010195065,0.00006772682,0.0010996923,0.00000783697,0.01575577,0.000025211233,0.00041319063,0.024732322],"study_design_scores_gemma":[0.014962351,0.00018436198,0.9204794,0.0005218214,0.00005585085,0.000011252954,0.0001378014,0.001864083,0.056239076,0.00025101396,0.0050802813,0.000212697],"about_ca_topic_score_codex":0.00018967025,"about_ca_topic_score_gemma":0.00033292547,"teacher_disagreement_score":0.040483307,"about_ca_system_score_codex":0.0004396097,"about_ca_system_score_gemma":0.0012104671,"threshold_uncertainty_score":0.933451},"labels":[],"label_agreement":null},{"id":"W4413419348","doi":"10.1002/cpdd.1601","title":"Pharmacokinetics and Pharmacodynamics of Faldaprevir Following Multiple Oral Rising Doses in Healthy Volunteers and Subjects with Gilbert's Syndrome","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; Pharmacodynamics; Dosing; Placebo; Pharmacology; Gastroenterology; Adverse effect; Internal medicine","score_opus":0.01964009221475031,"score_gpt":0.3547409551100993,"score_spread":0.33510086289534896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413419348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444765,0.0017391948,0.00017729707,0.0014716537,0.000995725,0.0009679816,0.000003629285,0.000032951044,0.00016393623],"genre_scores_gemma":[0.9901628,0.0017132048,0.005670712,0.0020677089,0.000023414765,0.000053788528,0.000015444131,0.000024910647,0.0002680517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974058,0.00018253524,0.0011866911,0.00056046725,0.00020273756,0.0004617558],"domain_scores_gemma":[0.998911,0.00056454353,0.00014610367,0.000114391965,0.000055314016,0.00020861893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012455493,0.00028560738,0.00096545473,0.00039031848,0.00007088289,0.0000079581905,0.00012593194,0.00015213109,0.000017829614],"category_scores_gemma":[0.000059672806,0.00024487148,0.00007196836,0.0005002603,0.00028820356,0.000092864335,0.000092588736,0.00065541023,0.0000011029728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047884914,0.0011256915,0.97588205,0.0011287825,0.00050769985,0.0011553603,0.0010914047,0.00013787049,0.0042155734,0.000023723089,0.00021721367,0.009726132],"study_design_scores_gemma":[0.04017504,0.00045426053,0.9368752,0.0015591284,0.00064471434,0.00006267819,0.00062778906,0.0046494105,0.009576694,0.00006088243,0.0047777463,0.0005364428],"about_ca_topic_score_codex":0.000057452944,"about_ca_topic_score_gemma":0.0004445091,"teacher_disagreement_score":0.039006844,"about_ca_system_score_codex":0.00013643363,"about_ca_system_score_gemma":0.0004908765,"threshold_uncertainty_score":0.9985569},"labels":[],"label_agreement":null},{"id":"W4413419631","doi":"10.1002/cpdd.1580","title":"Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Mental Health & Substance Use Services","funders":"H. Lundbeck A/S; Otsuka Pharmaceutical","keywords":"Aripiprazole; Medicine; Bipolar I disorder; Bipolar disorder; Schizophrenia (object-oriented programming); Internal medicine; Mood; Population; Hazard ratio; Mood disorders; Psychiatry; Confidence interval","score_opus":0.01852491266471569,"score_gpt":0.35802027590335916,"score_spread":0.3394953632386435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413419631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933515,0.0021456883,0.0002229389,0.0018565976,0.0004830744,0.0017441371,0.000016845761,0.000037272788,0.00014192848],"genre_scores_gemma":[0.9942241,0.00018204749,0.002022474,0.0018815494,0.000027959759,0.000883928,0.00017418491,0.000019498935,0.0005842598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971891,0.00036500127,0.0011575231,0.0006247118,0.00019466893,0.00046898887],"domain_scores_gemma":[0.9979801,0.0013462146,0.00014588815,0.00024065877,0.00012788379,0.0001592284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013045659,0.00027612748,0.0008375416,0.0006778748,0.00008458686,0.000009421241,0.0001704821,0.00018624023,0.0001000877],"category_scores_gemma":[0.00026033723,0.00022228053,0.00018337852,0.001130107,0.00014881407,0.000054225264,0.00009144591,0.00040927078,0.000017824856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009042263,0.0062125977,0.96059805,0.000043135005,0.0017750494,0.000035345365,0.00069642515,0.0001820165,0.000009760591,0.00000562336,0.0009979275,0.020401789],"study_design_scores_gemma":[0.02393034,0.00045942,0.8938699,0.00004891095,0.00077884074,1.9473212e-7,0.00011037616,0.00014256136,0.00023996795,0.000015903715,0.08020839,0.0001952285],"about_ca_topic_score_codex":0.000085301865,"about_ca_topic_score_gemma":0.002826261,"teacher_disagreement_score":0.07921046,"about_ca_system_score_codex":0.00032217512,"about_ca_system_score_gemma":0.000722847,"threshold_uncertainty_score":0.9064337},"labels":[],"label_agreement":null},{"id":"W4414018844","doi":"10.1002/cpdd.1586","title":"Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"AstraZeneca","keywords":"Pharmacokinetics; Medicine; Placebo; Adverse effect; Internal medicine; Randomized controlled trial; Gastroenterology; Pharmacology; Pathology","score_opus":0.04614544387618751,"score_gpt":0.4838551436213657,"score_spread":0.4377096997451782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414018844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929747,0.0026576277,0.000009102213,0.0015470592,0.00024770218,0.0017482105,0.000007665395,0.0000081223925,0.0007998355],"genre_scores_gemma":[0.997112,0.0019609623,0.00045348023,0.00014772257,0.00004471688,0.00005205024,0.000014416009,0.000009932892,0.00020476314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965275,0.0009900717,0.0012959045,0.00047921838,0.00040817293,0.00029916153],"domain_scores_gemma":[0.9980107,0.001376966,0.00020909045,0.00010232411,0.00016429598,0.0001366444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058882707,0.00023016847,0.00094902096,0.0003792128,0.000072742485,0.000007313066,0.000101038706,0.000105734216,0.000072519855],"category_scores_gemma":[0.000491824,0.00019224404,0.0000488801,0.00033525305,0.00045346428,0.00006109897,0.0003429346,0.00060145644,8.535479e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005262334,0.001963288,0.70545286,0.0005663354,0.00033729264,0.00008675047,0.0022086056,0.000010572208,0.0021766592,0.000004696355,0.00013369421,0.28179693],"study_design_scores_gemma":[0.027476417,0.00073255086,0.9571075,0.00031581672,0.00034434473,0.000016107419,0.0003376141,0.0041585458,0.008895728,0.000034086766,0.00043533806,0.00014599045],"about_ca_topic_score_codex":0.00009300367,"about_ca_topic_score_gemma":0.00008373048,"teacher_disagreement_score":0.28165093,"about_ca_system_score_codex":0.000093048126,"about_ca_system_score_gemma":0.00039194376,"threshold_uncertainty_score":0.7839485},"labels":[],"label_agreement":null},{"id":"W4415846907","doi":"10.1002/cpdd.1623","title":"What Does an Editor Do in 2025?","year":2025,"lang":"en","type":"editorial","venue":"Clinical Pharmacology in Drug Development","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Publishing; Conversation; Context (archaeology); Clinical trial; Task (project management); Alternative medicine; Clinical pharmacology; Clinical Practice","score_opus":0.30004322525617194,"score_gpt":0.6214337519721888,"score_spread":0.3213905267160168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415846907","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002214307,0.0003060852,0.00023617293,0.0012839393,0.993291,0.001901612,0.000115434756,0.00014746361,0.00050395116],"genre_scores_gemma":[0.000026638743,0.0035966649,0.19875035,0.0010030518,0.7907175,0.0008575447,0.00007715633,0.00010430965,0.004866815],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9781719,0.008723741,0.007981012,0.0024853416,0.0013542523,0.0012837726],"domain_scores_gemma":[0.6406134,0.35581917,0.001382977,0.0010545988,0.00054344145,0.00058645115],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.031366833,0.0009943128,0.0039355485,0.00065700395,0.00010904443,0.00018226934,0.0021990053,0.0039809197,0.0017909976],"category_scores_gemma":[0.19660242,0.0008090833,0.00038510148,0.0006935765,0.0007364748,0.0003258113,0.001275818,0.0071917437,0.00019752952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007302776,0.002543357,0.0002935391,0.00058805797,0.00027918938,0.00027052726,0.00048753803,0.0000021655717,0.0000024442675,0.00025285518,0.9740689,0.020481165],"study_design_scores_gemma":[0.0053686546,0.00010215804,0.00019837284,0.001343808,0.00020271853,2.259251e-7,0.00018682869,0.00002065956,0.000102450555,0.1868938,0.8047478,0.0008325136],"about_ca_topic_score_codex":0.000020226216,"about_ca_topic_score_gemma":0.0004274879,"teacher_disagreement_score":0.34709543,"about_ca_system_score_codex":0.0009084,"about_ca_system_score_gemma":0.0040457603,"threshold_uncertainty_score":0.999436},"labels":[],"label_agreement":null}]}